US Pat. No. 10,213,376

METHOD OF SUPPRESSING COLORATION OF CATECHINS AND A DENTIFRICE COMPOSITION

KAO CORPORATION, Tokyo (...

1. A dentifrice composition comprising hydrogel particles (A), a binder (B) and water (C), wherein:the hydrogel particles (A) comprise catechins (A1), a water-soluble polymer (A2) capable of forming a water-insoluble complex with catechins, a gel former (A3) and water (A4);
the polymer (A2) is selected from polyvinyl pyrrolidone, polyvinyl alcohol and hydroxyethyl cellulose;
the gel former (A3) is at least one selected from agar, ?-carrageenan, ?-carrageenan, ?carrageenan, furcelleran, alginate, propylene glycol alginate, guar gum, locust bean gum, tamarind seed polysaccharides, tara gum, quassia gum, pectin, arabinogalactan, xanthan gum, scleroglucan, pullulan, dextran, gellan gum, curdlan, gelatin, albumin, casein, soy protein, wheat protein, carboxymethyl cellulose, methyl cellulose, microcrystalline cellulose, starch, starch phosphate and starch glycolate;
the hydrogel particles (A) have an average particle size of 5 to 5000 ?m;
the binder (B) is at least one selected from sodium alginate, carboxymethylcellulose sodium, carrageenan, xanthan gum, sodium polyacrylate, hydroxyethyl cellulose, hydroxypropyl cellulose, pectin, tragacanth gum, gum arabic, guar gum, karaya gum, locust bean gum, gellan gum, tamarind gum, psyllium seed gum, polyvinyl alcohol, sodium chondroitin sulfate and a methoxy ethylene-maleic anhydride copolymer;
the ratio (A2/A1) of the polymer (A2) to the catechins (A1) in the hydrogel particles (A) is 1 to 4 times by weight; and
the dentifrice composition is contained in a storage container.
US Pat. No. 10,214,657

SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS

EASTMAN KODAK COMPANY, R...

1. A non-aqueous silver precursor composition consisting essentially of:at least 1 weight % of one or more (a) polymers selected from one or more of cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and carboxymethyl cellulose, based on the total weight of the non-aqueous silver precursor composition;
(b) reducible silver ions; and
(c) an organic solvent medium consisting of:
(i) one or more hydroxylic organic solvents, each of which has an ?-hydrogen atom and a boiling point at atmospheric pressure of at least 100° C. and less than 500° C., and
(ii) a nitrile-containing aprotic solvent or a carbonate-containing aprotic solvent or both a nitrile-containing aprotic solvent and a carbonate-containing aprotic solvent, all of which are different from all of the (i) one or more hydroxylic organic solvents, each having a boiling point at atmospheric pressure of at least 100° C. and less than 500° C.;
wherein the (b) reducible silver ions are present in the non-aqueous silver precursor composition in an amount of at least 0.1 weight % and up to and including 400 weight %, based on the total weight of the one or more (a) polymers.
US Pat. No. 10,214,913

POWDER BASED BALANCING LAYER

VALINGE INNOVATION AB, V...

1. A method of manufacturing a building panel with a decorative surface layer, a core and a balancing and/or protective layer, wherein the method comprises the steps:applying a first layer of a first powder based mix, comprising wood fibres and a thermosetting binder, on a core;
applying a liquid substance on the first powder based mix;
drying the first powder based mix;
turning the core with the dried first powder based mix such that the first powder based mix points downwards and an upper part of the core faces upwards;
applying a second layer on the upper part of the core; and
curing the first and second layers by providing heat and pressure, wherein the first layer forms the balancing and/or protective layer and the second layer forms the decorative surface layer in the building panel.
US Pat. No. 10,213,378

SINGLE DOSE NON-ADJUVANTED CUTANEOUS TETANUS VACCINE AND USES THEREOF

Sporos Therapeutics, LLC,...

1. A method for preventing or treating tetanus infection in a pregnant subject, comprising administering a non-adjuvanted tetanus toxoid vaccine to the skin of the subject; wherein the non-adjuvanted tetanus toxoid vaccine comprises 3% polyvinyl alcohol and 10% sucrose as excipients.
US Pat. No. 10,214,658

METHOD OF THREE-DIMENSIONAL PRINTING

LOTTE CHEMICAL CORPORATIO...

1. A method of three-dimensional (3D) printing, the method comprising:heating a composition comprising a polymer base including atactic polypropylene having a weight average molecular weight of 50,000 to 1,000,000, a density of 0.8 to 0.9 g/ml, and isotacticity (Pentad I.I, mmmm) of 5 to 20%, wherein a melting index (210° C., 2.16 kg) of the polymer base is 0.5-30 g/10 minutes;
extruding the composition as a filament; and
applying the extruded filament in one or more layers,
wherein a solidification rate (measuring melting indexes (MI, 150° C., 10 kg)) of the filament is less than or equal to 2 g/10 minutes and a melting rate (measuring melting indexes (MI, 180° C., 10 kg)) of the filament is greater than or equal to 10 g/10 minutes, and
wherein hardness of the polymer base is less than or equal to Shore A 90.
US Pat. No. 10,217,219

SYSTEMS AND METHODS FOR AUTOMATED ANALYSIS OF CELLS AND TISSUES

YALE UNIVERSITY, New Hav...

1. A computer implemented method for localizing and quantitating a particular biomarker present in individual cells of interest contained in a tissue sample, comprising:a) incubating the tissue sample with a stain that specifically labels the biomarker;
b) obtaining, using an optical imaging device, a first in-focus image and a second out-of-focus image, each of the first in-focus image and the second out-of-focus image comprising respective pixel locations having an intensity value for each pixel in the tissue sample;
c) subtracting the second out-of-focus image from the first in-focus image to obtain a third image, wherein for each pixel location a percentage of the out-of-focus image pixel intensity is subtracted from the corresponding in-focus image pixel intensity to obtain the third image; and
d) analyzing the third image to obtain a stain intensity and location of the stain so as to thereby localize and quantitate the biomarker.
US Pat. No. 10,217,475

HEADSET AND METHOD FOR CONTROLLING SAME

LG ELECTRONICS INC., Seo...

1. A headset, comprising:a wireless communication unit configured to provide wireless communication;
a first microphone mounted on the headset;
a second microphone to be placed within an ear of the user wearing the headset; and
a controller configured to:
receive a phone call via the wireless communication unit from an external device,
select either one of the first microphone or the second microphone to receive a voice signal of the user responding to the received phone call,
in response to the selection of the first microphone, receive the voice signal of the user through the first microphone, correct a sound quality of the voice signal received through the first microphone, and transmit the corrected voice signal to the external device, and
in response to the selection of the second microphone, receive the voice signal of the user from the external auditory canal of the ear of the user having the second microphone placed therein, correct a sound quality of the voice signal received through the second microphone, and transmit the corrected voice signal to the external device,
wherein the controller is further configured to:
automatically turn on a display unit of the external device, and
control the external device to display a call sound quality setting icon for setting a call sound quality on the display unit of the external device.
US Pat. No. 10,213,379

FORMULATIONS FOR THE RECTAL ADMINISTRATION OF THROMBOLYTICALLY-ACTIVE AGENTS

CENTRO DE INGENIERIA GENE...

1. A method for treating hemorrhoid disease in a human in need thereof, wherein the method consists essentially of administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a streptokinase (SK) and a pharmaceutically acceptable diluent, carrier or excipient, wherein the pharmaceutical composition is administered rectally as a suppository, wherein the SK is in an amount of 50,000 IU to 150,000 IU per gram of composition, wherein administration is for 4 to 6 days, wherein the treatment occurs without systemic thrombolytic effects, and wherein the pharmaceutical composition effectively treats hemorrhoid disease.
US Pat. No. 10,214,659

AQUEOUS COMPOSITIONS HAVING POLYALKOXYLATES FOR IMPROVED OPEN TIME

Dow Global Technologies L...

1. An aqueous composition comprising:(i) an aqueous polymer composition of one or more emulsion polymers, one or more aqueous dispersion polymers, or mixtures thereof, and
(ii) from 0.1 to 5 wt. %, based on the total weight of solids in the aqueous composition, one or more polyalkoxylates having from 2 to 15 polyalkoxylate chains and an ethylene oxide (EO) content ranging from 20 to 70 wt. %, based on the total weight of polyalkoxylate solids in the aqueous composition.
US Pat. No. 10,213,380

METHOD OF TREATING EAR PAIN

Try This First, Inc., Wa...

1. A method of treating an ear infection comprising:administering an effective amount of an antibiotic-free salivary-producing hard candy composition to an individual suffering from an ear infection,
wherein said composition comprises:
a sweetening agent;
a natural flavoring agent;
an extract; and
citric acid; and
wherein said hard candy composition is shaped to include a first surface that is convex and a second surface that is flat,
wherein said first surface is configured to fit within an oral cavity of the individual and to contact a roof of the individual's oral cavity, and
wherein the second surface is configured to contact the tongue of the individual, and
wherein the first surface and the second surface are arranged such that when the individual sucks on the hard candy composition a negative pressure is formed within the individual's oral cavity that promotes drainage of fluid from the individual's Eustachian tube.
US Pat. No. 10,214,660

TWO-COMPONENT COATING COMPOSITIONS AND COATINGS PRODUCED THEREFROM FOR IMPROVING EROSION RESISTANCE

BASF Coatings GmbH, Muen...

1. A solvent-based two-component coating composition, comprising(1) a paint base component comprising
(A) at least one polycarbonate diol,
(B) at least one hydroxyl-containing acrylate resin, polyester resin and/or polyester acrylate resin having a hydroxyl number of 75 to 500 mg KOH/g, and
(C) at least one filler modified with at least one organosilane, and
(2) a hardener component comprising
(D) at least one organic polyisocyanate,
wherein the coating composition has a viscosity of 50 to 2000 mPa·s at a shear stress of 1000 l/s and a temperature of 23° C. and a proportion of organic solvents of 100 to 350 g/L.
US Pat. No. 10,213,381

SOLID SOLUTION COMPOSITIONS AND USE IN CHRONIC INFLAMMATION

infirst Healthcare Limite...

1. A solid solution pharmaceutical composition comprising:a) 25% to 31% by weight of an ibuprofen, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof;
b) 34% to 40% by weight of a hard fat that includes a triglyceride mixture;
c) 22% to 28% by weight of a liquid lipid mixture that includes monoglyceride; and
d) 7% to 13% by weight of a liquid glycol polymer.
US Pat. No. 10,214,661

ORGANIC SILICON COATING

HUNAN SOKAN NEW MATERIALS...

1. An organic silicon coating, consisting essentially of:20 to 40 parts by weight of methyl vinyl organic silicon polymer,
1 to 6 parts by weight of methyl phenyl organic silicon polymer,
5 to 15 parts by weight of hydrogenated silicone oil,
5 to 10 parts by weight of fluorinated acrylate monomer,
5 to 15 parts by weight of silicon dioxide,
0.2 to 2 parts by weight of inhibitor,
0.1 to 1 part by weight of auxiliary,
0.1 to 1 part by weight of thermal initiator,
30 to 50 parts by weight of organic solvent,
and 2 to 5 parts by weight of metal catalyst,
wherein the inhibitor has a deblocking temperature of ?80° C. against the metal catalyst, and
wherein the auxiliary is selected from the group consisting of a leveling agent, an anti-settling agent, a wetting and dispersing agent, and combinations thereof.
US Pat. No. 10,213,383

HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS

NOVARTIS AG, Basel (CH)

1. A method for a large-scale manufacture of a squalene-containing oil-in-water emulsion, comprising steps of:(i) forming providing a first emulsion having a first average oil droplet size, wherein the first average oil droplet size is 5000 nm or less and/or wherein the number of oil droplets having a size of >1.2 ?m in the first emulsion is 5×1011/ml or less;
(ii) microfluidizing the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size, wherein the number of oil droplets having a size of >1.2 ?m in the second emulsion is 5×1010/ml or less; and
(iii) filtrating the second emulsion using a first hydrophilic polyethersulfone membrane layer having a pore size >0.3 ?m and a second hydrophilic polyethersulfone membrane layer having a pore size <0.3 ?m, thereby providing a squalene-containing oil-in-water emulsion,
wherein at least one of the first and the second hydrophilic polyethersulfone membrane layers is an asymmetric membrane,
wherein the squalene-containing oil-in-water emulsion has a volume of more than or equal to 50 liters; and,
(iv) filling the oil-in-water emulsion into one or more sterile closed systems.
US Pat. No. 10,213,895

POLISHING PAD AND METHOD FOR MANUFACTURING SAME

FUJIBO HOLDINGS, INC., C...

1. A polishing pad comprising:a resin-containing polishing cloth having a polishing cloth base impregnated with a polyurethane resin and silicon carbide, wherein
the silicon carbide has a particle diameter in a range from 0.2 to 1.5 ?m, and
the content of the silicon carbide in the resin-containing polishing cloth is in a range from 90 to 350 parts by mass relative to 100 parts by mass of the polishing cloth base.
US Pat. No. 10,214,920

COMPOSITE EPOXY RESIN BOARD AND FORMING METHOD THEREOF

GUANGDONG OUMING NEW MATE...

1. A composite epoxy resin board made from a raw material comprising following components by weight: 5% to 95% waste prepreg powders, 1% to 95% powders from waste printed circuit boards (PCBs), 1% to 90% powders from waste epoxy plastic products or phenolic plastic products, 0% to 80% stone powders, 0% to 45% PVC powders and/or PE powders and/or HDPE powders, 0% to 20% copper powders, 0% to 20% aluminum powders, 0% to 5% color pigments, 0% to 80% straw, bamboo and wood powders, 0% to 20% chemical fiber powders, 0% to 80% calcium carbonate powders, 0% to 20% adhesives, 0% to 1% antioxidants, 0% to 1% reinforcing agents, 0% to 1% carbide stabilizers, and 0% to 5% coupling agents, and a sum of which is 100%, wherein:the stone powders are made from wastes produced from marble mining or processing;
the straw, bamboo and wood powders are one or more members selected from a group consisting of straw powders, wood sawdust and bamboo sawdust;
the adhesives are one or more members selected from a group consisting of phenolic-resin adhesives, epoxy resin adhesives, isocyanate adhesives and polyvinyl alcohol adhesives.
US Pat. No. 10,213,387

ORAL DRUG DELIVERY SYSTEM

Sun Pharma Advanced Resea...

1. An orally administerable drug delivery system in the form of a coated tablet, comprising:(1) a core comprising one or more active ingredient composition layers and one or more separate reactive composition layers,
(i) the one or more active ingredient composition layers comprising at least one therapeutically active ingredient and at least one pharmaceutically acceptable excipient, wherein in at least one active ingredient composition layer, at least one pharmaceutically acceptable excipient is a rate controlling excipient and
(ii) the reactive composition layer comprising a reactive ingredient; and
(2) a water insoluble polymer coating surrounding the core and capable of being dissolved, disintegrated, or weakened in the presence of the reactive ingredient released from the reactive composition,
wherein one or more of the reactive composition layers is located in an immediate vicinity of one or more preselected portions of the coating in order to be in communication with said preselected portions of the coating, and the one or more therapeutically active ingredient composition layers are in the vicinity of another portion of the coating; and
wherein the at least one or more preselected portions of the coating that is in communication with the reactive layer is removed after contact with an aqueous environment and wherein the remaining portion of the coating is not removed.
US Pat. No. 10,213,132

METHOD TO EVALUATE PATIENTS FOR THORACIC OUTLET SYNDROME

Vanguard Specialty Imagin...

1. A method of generating and outputting a plurality of three-dimensional models and a plurality of series of images to evaluate a human subject for a presence or absence of thoracic outlet syndrome (TOS) which method comprises:generating a first three-dimensional model of a brachial plexus on an affected side(s), the first three-dimensional model generated based at least in part on reconstruction and reformation of a first set of magnetic resonance imaging (MRI) slices obtained in each of three planes, in the absence of a contrast agent, with a subject in a supine position with both arms in a neutral position by a side of a body of the subject, wherein obtaining the first set of MRI slices is configured to comprise:
obtaining a gradient echo T1, spin echo T1, or fast spin echo T2-weighted sequence that comprises sagittal slices that cover scalene triangle, costoclavicular space, and retropectoralis spaces on an affected side(s);
obtaining another gradient echo T1, spin echo T1, or fast spin echo T2-weighted sequence that comprises axial slices that cover mid and lower cervical spinal portions, lower neck, the brachial plexus, supraclavicular space, superior mediastinum, and lung apex on the affected side(s); and
obtaining a Short Tau Inversion Recovery (STIR) sequence that comprises slices that cover a volume of the brachial plexus on the affected side(s);
outputting a first series of images including the first set of MRI slices, to be displayed on a workstation to determine, based at least in part on the first set of MRI slices, a presence or absence of stenosis and to determine the presence or absence of thoracic outlet syndrome (TOS);
outputting the first three-dimensional model to the workstation to determine the presence or absence of thoracic outlet syndrome (TOS);
obtaining a second set of MRI slices obtained in one or more planes, in the absence of the contrast agent, with the subject in a supine position with both arms placed in abduction and external rotation, by imaging upper chest and neck portions and a supraclavicular fossa region on the affected side(s), wherein the second set of MRI slices is configured to be obtained by the gradient echo T1, spin echo T1, or fast spin echo T2-weighted sequence that comprises sagittal slices that cover scalene triangle, costoclavicular space and retropectoralis space on the affected side(s);
outputting a second series of images including the second set of MRI slices, to be displayed on the workstation to determine, based at least in part on the second set of MRI slices, the presence or absence of stenosis and to determine the presence or absence of thoracic outlet syndrome (TOS);
generating a second three-dimensional model of arteries on the affected side(s), the second three-dimensional model generated based at least in part on reconstruction and reformation of a plurality of slices from a contrast-enhanced magnetic resonance angiogram (MRA), wherein the plurality of MRA slices images subclavian and axillary arteries on both sides of the subject, wherein the plurality of MRA slices are configured to be obtained by administering a diluted contrast agent comprising 50% gadolinium into a vein on a first side of the subject such that the contrast agent enters arteries on both sides of the subject and veins on both sides of the subject and obtaining a contrast-enhanced MRA, which images, in the subject, the contrast agent;
outputting a third series of images including the plurality of MRA slices, to be displayed on the workstation to determine, based at least in part on the plurality of MRA slices, a presence or absence of stenosis, external compression, or aneurysm, if any, in each of the subclavian and the axillary arteries by assessing vascular contrast enhancement, on both sides of the subject and to determine the presence or absence of thoracic outlet syndrome (TOS);
outputting the second three-dimensional model to the workstation to determine the presence or absence of thoracic outlet syndrome (TOS);
generating a third three-dimensional model of veins on the affected side(s), the third three-dimensional model generated based at least in part on reconstruction and reformation of a plurality of slices from a magnetic resonance venogram (MRV), wherein the plurality of MRV slices images the subclavian, axillary, and brachiocephalic veins on both sides of the subject, wherein the plurality of MRV slices are configured to be obtained by administering the diluted contrast agent comprising 50% gadolinium into the vein on the first side of the subject such that the contrast agent enters arteries on both sides of the subject and veins on both sides of the subject and obtaining the MRV, which images, in the subject, the contrast agent;
outputting a fourth series of images including the plurality of MRV slices, to be displayed on the workstation to determine, based at least in part on the plurality of MRV slices, the presence or absence of stenosis or external compression in each of the subclavian, axillary, and brachiocephalic veins on both sides of the subject by assessing vascular contrast enhancement, on both sides of the subject and to determine the presence or absence of thoracic outlet syndrome (TOS); and
outputting the third three-dimensional model to the workstation to determine the presence or absence of thoracic outlet syndrome (TOS).
US Pat. No. 10,213,388

ABUSE RESISTANT ORAL DOSAGE FORMS

Elite Laboratories, Inc.,...

1. A compressed microtablet that is coated with a membrane, comprisinga compressed uncoated microtablet having a major dimension that is about 0.5 to about 3. 0 mm and is a compression of a dry powder blend comprising at least one opioid antagonist, at least one compression aid, and at least one lubricant;
wherein the uncoated microtablet comprises about 10 to about 30 weight percent, by weight of the uncoated microtablet, of the at least one opioid antagonist;
wherein the at least one opioid antagonist is naltrexone, naloxone, nalmephene, cyclazacine, or levallorphan and is dispersed substantially throughout said uncoated microtablet,
wherein the at least one compression aid is microcrystalline cellulose, lactose, dicalcium phosphate, sucrose, starch, stearic acid, polyethylene glycol, a wax, or a combination thereof; and
wherein the at least one lubricant is calcium strearate, magnesium stearate, zinc stearate, strearic acid, talc, hydrogenated vegetable oil, or a combination thereof;
a membrane coating the compressed uncoated microtable, wherein the membrane is about 16 to about 80 weight percent, by weight of the coated microtablet, the membrane comprising:
about 2 weight percent to about 89 weight percent, by weight of the membrane, of a water-retardant polymer that is a non-ionic poly(ethylacrylate-co-methacrylate) polymer in which the molar ratio of ethyl acrylate to methyl methacrylate is about 2:1; and
about 5 weight percent to about 50 weight percent, by weight of the membrane, of an additive that is calcium stearate, magnesium stearate, zinc stearate, stearic acid, glyceryl monostearate, hydrogenated vegetable oil, talc, or a combination thereof;
wherein the weight gain of the uncoated microtablet after the application of the membrane is from about 105 to about 500 weight percent increase;
and
an opioid agonist layer coated onto the membrane, wherein the opioid agonist comprises oxycodone, morphine, hydrocodone, or codeine;
wherein said coated microtablet releases no more than about 0.5 weight percent of said opioid antagonist within 36 hours when measured using the USP Apparatus I (Basket) Method at 100 rpm at 37° C. in simulated gastric fluid for one hour followed by simulated intestinal fluid thereafter.
US Pat. No. 10,214,668

ADHESIVE COMPOSITION AND ARTICLE INCLUDING THE SAME

ND Industries, Inc., Cla...

14. An article comprising:a substrate having a surface; and
an adhesive composition disposed on said surface;
wherein said adhesive composition is as set forth in claim 12.
US Pat. No. 10,217,999

RECHARGEABLE LITHIUM BATTERY

Samsung SDI Co., Ltd., Y...

1. A rechargeable lithium battery, comprising:a negative electrode and a positive electrode,
wherein a specific surface area per a unit area of the positive electrode is 3 times to about seven times as large as a specific surface area per a unit area of the negative electrode,
wherein the specific surface area per the unit area of the positive electrode is calculated from a specific surface area and amount of each component of the positive electrode and a loading level of the positive electrode, and
wherein the specific surface area per the unit area of the negative electrode is calculated from a specific surface area and amount of each component of the negative electrode and a loading level of the positive electrode.
US Pat. No. 10,213,389

CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

Recro Gainesville LLC, G...

1. A hard gelatin capsule comprising:a population of isosorbide dinitrate immediate-release beads comprising: isosorbide dinitrate in an amount from about 2.5 mg to about 30 mg, mannitol, povidone, silicon dioxide, and sugar spheres;
a population of isosorbide dinitrate sustained-release beads comprising: isosorbide dinitrate in an amount from about 2.5 mg to about 30 mg, mannitol, povidone, silicon dioxide, sugar spheres, triethyl citrate, an ammonio methacrylate copolymer, and a methacrylic acid copolymer;
a population of hydralazine immediate-release beads comprising: hydralazine, or a salt thereof, in an amount from about 0.5 mg to about 60 mg, povidone, silicon dioxide, sugar spheres, and citric acid; and
a population of hydralazine sustained-release beads comprising: hydralazine, or a salt thereof, in an amount from about 2.5 mg to about 30 mg, povidone, silicon dioxide, sugar spheres, citric acid, an ammonio methacrylate copolymer, a methacrylic acid copolymer, and triethyl citrate.
US Pat. No. 10,214,669

COMPOSITIONS COMPRISING 2,3-DICHLORO-1,1,1-TRIFLUOROPROPANE, 2-CHLORO-1,1,1-TRIFLUOROPROPENE, 2-CHLORO-1,1,1,2-TETRAFLUOROPROPANE OR 2,3,3,3-TETRAFLUOROPROPENE

THE CHEMOURS COMPANY FC, ...

1. A composition comprising HFO-1234yf, HFC-245cb, HFC-245fa, HFO-1234ze, HCFO-1233zd and HCFO-1233xf.
US Pat. No. 10,218,001

OLIVINE OXIDE-CONTAINING POSITIVE ACTIVE MATERIAL FOR RECHARGEABLE LITHIUM BATTERY WITH IMPROVED ELECTRO-CONDUCTIVITY, RATE CHARACTERISTICS AND CAPACITY CHARACTERISTICS, METHOD FOR MANUFACTURING THE SAME, AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAM

Samsung SDI Co., Ltd., G...

1. A rechargeable lithium battery comprising:a positive electrode comprising a positive active material, the positive active material comprising:
a composite oxide represented by the following Chemical Formula 1:
LixMyM?zXO4-wAw  [Chemical Formula 1]
wherein, in Chemical Formula 1,
M and M? are independently selected from the group consisting of iron (Fe), aluminum (Al), boron (B), cobalt (Co), chromium (Cr), copper (Cu), gallium (Ga), germanium (Ge), hafnium (Hf), magnesium (Mg), manganese (Mn), molybdenum (Mo), niobium (Nb), nickel (Ni), tin (Sn), titanium (Ti), vanadium (V), zinc (Zn), zirconium (Zr), and a combination thereof,
X is selected from the group consisting of phosphorus (P), arsenic (As), bismuth (Bi), molybdenum (Mo), antimony (Sb), and a combination thereof,
A is selected from the group consisting of fluorine (F), sulfur (S), and a combination thereof, and
0 germanium (Ge) metal, gallium (Ga) metal, or a combination thereof adhered to a surface of the composite oxide;
a negative electrode comprising a negative active material; and
an electrolyte.
US Pat. No. 10,213,391

PHARMACEUTICAL COMPOSITIONS COMPRISING HEMP AND TURMERIC TO TREAT PAIN AND INFLAMMATION

1. A tablet or capsule consisting essentially of curcumin, cannabidiol, talc, methacrylic acid-ethyl acrylate copolymer, triethyl citrate, and a simethicone emulsion.
US Pat. No. 10,214,671

REFRIGERATOR OIL AND WORKING FLUID COMPOSITION FOR REFRIGERATOR

1. A working fluid composition for a refrigerating machine, consisting of:a refrigerating machine oil consisting of a base oil and optionally an additive, wherein the base oil comprises an ester of a polyhydric alcohol and a fatty acid with a content of a C5-C9 branched fatty acid of 70-100% by mole, wherein the polyhydric alcohol is a mixture of pentaerythritol and di-(pentaerythritol); and
a refrigerant consisting of only one fluoropropene refrigerant.
US Pat. No. 10,218,002

POSITIVE ELECTRODE MIX FOR SECONDARY BATTERIES INCLUDING IRREVERSIBLE ADDITIVE

LG Chem, Ltd., (KR)

1. A positive electrode mix for secondary batteries comprising an irreversible additive that decreases irreversible efficiency of a positive electrode active material and a positive electrode,wherein the irreversible additive is a lithium molybdenum sulfide represented by Formula 1 below:
Li2+xMo6-yMyS8-z  (1),
wherein ?0.1?x?0.5, 0?y?0.5, ?0.1?z?0.5, and M is a metal or transition metal cation having an oxidation number of +2 to +4, and
the irreversible additive has an operation voltage of 1.0 V to 2.5 V with respect to Li, and
wherein the positive electrode mix further comprises a positive electrode active material comprising a lithium transition metal oxide represented by Formula 2 or 3 below:
LixMyMn2-yO4-zAz  (2),
wherein in Formula 2:
M is at least one element selected from the group consisting of Al, Mg, Ni, Co, Fe, Cr, V, Ti, Cu, B, Ca, Zn, Zr, Nb, Mo, Sr, Sb, W, Ti and Bi;
A is at least one monovalent or divalent anion; and
0.9?x?1.2, 0 (1?x)LiM?O2-yAy-xLi2MnO3-y?Ay?  (3),
wherein in Formula 3:
M? is MnaMb;
M is at least one selected from the group consisting of Ni, Ti, Co, Al, Cu, Fe, Mg, B, Cr, Zr, Zn and Period II transition metals;
A is at least one selected from the group consisting of anions such as PO4, BO3, CO3, F and NO3; and
0
US Pat. No. 10,218,003

ANODE AND SECONDARY BATTERY INCLUDING THE SAME

Samsung SDI Co., Ltd., Y...

1. An anode for a secondary battery, the anode comprising:a negative electrode active material layer on a current collector, the negative electrode active material layer comprising:
a negative electrode active material, a binder, and a conductive material, wherein the negative electrode active material comprises at least one pore on a surface thereof, and the conductive material is located at the pore of the negative electrode active material,
wherein the conductive material has a diameter of 10 nm to 50 nm, and
wherein the pore of the negative electrode active material has a width of 50 nm to 10 ?m, and a depth of 20 nm to 10 ?m.
US Pat. No. 10,213,393

COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE

1. A method of treating Parkinson's disease in a patient, comprising:i) administering to the patient once daily in the morning a pharmaceutical composition comprising about 129 mg of amantadine free base equivalent for one week;
ii) increasing the dose of amantadine by administering to the patient once daily in the morning a pharmaceutical composition comprising about 193 mg of amantadine free base equivalent;
wherein each of the pharmaceutical compositions comprises i) an extended release component comprising amantadine free base equivalent; and ii) an immediate release component comprising about 48 mg of amantadine free base equivalent, wherein each of the pharmaceutical compositions is an osmotic device comprising an osmotic agent and an osmotic coating,
wherein the maximum daily dose of amantadine is about 322 mg of amantadine free base equivalent,
wherein each of the pharmaceutical compositions provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is between about 40% and about 70% of the dC/dT provided by the same quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, and
wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between 0 and 4 hours after administration.
US Pat. No. 10,214,673

THERMALLY CONDUCTIVE, PLATE-SHAPED PIGMENT COATED WITH ALUMINIUM OXIDE

MERCK PATENT GMBH, Darms...

1. A thermally conductive pigment consisting of a flake-form, dielectric substrate and a single layer located thereon, said single layer comprises at least 80% by weight, based on the total weight of the layer, of aluminium oxide and/or aluminium oxide hydrate and 0.1 to 10% by weight, based on the total weight of the layer, of MgO, Cr2O3 or SiO2; andwherein the substrate is selected from the group consisting of natural mica flakes, synthetic mica flakes, kaolin flakes, talc flakes and mixtures thereof.
US Pat. No. 10,213,394

COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE

1. A method of treating a drug-induced extrapyramidal reaction in an adult patient, comprising:i) administering to the patient once daily in the morning a pharmaceutical composition comprising about 129 mg of amantadine free base equivalent for one week;
ii) increasing the dose of amantadine by administering to the patient once daily in the morning a pharmaceutical composition comprising about 193 mg of amantadine free base equivalent;
wherein each of the pharmaceutical compositions comprises i) an extended release component comprising amantadine free base equivalent; and ii) an immediate release component comprising about 48 mg of amantadine free base equivalent, wherein each of the pharmaceutical compositions is an osmotic device comprising an osmotic agent and an osmotic coating,
wherein the maximum daily dose of amantadine is about 322 mg of amantadine free base equivalent,
wherein each of the pharmaceutical compositions provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is between about 40% and about 70% of the dC/dT provided by the same quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, and
wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between 0 and 4 hours after administration.
US Pat. No. 10,213,396

PATCH TO ENHANCE LOCALLY FAT METABOLISM, USING THERMOPLASTIC ELASTOMER GEL COMPOSITION INCLUDING CAPSAICIN

SENNY STUDIO CO., LTD., ...

1. A patch to enhance locally fat metabolism, using a thermoplastic elastomer (TPE) gel composition including capsaicin, which is applied to the skin surface, comprising:a skin adhering layer formed of 3˜12 wt % of styrene ethylene butylene styrene (SEBS) or styrene ethylene ethylene propylene styrene (SEEPS), 44˜53 wt % of an adhesive agent; 44˜53 wt % of mineral oil, and 0.001˜0.009 wt % of capsaicin, the skin adhering layer having a top surface and a bottom surface;
a base layer secured to the bottom surface of the skin adhering layer, to provide support for the patch; and
a removable paper/film layer secured to the top surface of the skin adhering layer, to protect the skin adhering layer prior to use.
US Pat. No. 10,214,677

BREAKER FLUIDS AND METHODS OF USE THEREOF

M-I L.L.C., Houston, TX ...

1. A method of breaking a filtercake in a wellbore, comprising:circulating a breaker fluid into the wellbore having a filtercake on the walls thereon, the filtercake including copolymer formed from at least one acrylamide monomer and at least one sulfonated anionic monomer, the breaker fluid comprising:
a base fluid; and
a mixture of hydrolysable esters of dicarboxylic acids comprising about 27-67 wt. % dimethyl glutarate, about 9-28 wt. % dimethyl succinate, and about 4-22 wt. % dimethyl adipate.
US Pat. No. 10,215,701

METHOD OF ASSESSING CHEMICALS IN PRODUCED FLUIDS

Lux Assure Limited, Edin...

1. A method of monitoring water-soluble treatment chemicals in a fluid that is immiscible with water and which may or may not contain some aqueous fluid, where said water-soluble treatment chemical is a hydrate inhibitor, the method comprising:a. obtaining a sample of said fluid;
b. adding a first reagent to the fluid sample, wherein the first reagent is an oxidising agent being reactive with the treatment chemical to produce a first product, wherein the first product is an aldehyde;
c. adding a second reagent to the fluid sample, wherein the second reagent is an aldehyde reactive reagent being reactive with the first product in step (b) to produce an optically detectable second product wherein the second reagent is Fluoral P; and
d. detecting an optically detectable product;wherein the detection step takes place without separation of the aqueous phase containing the treatment chemicals from the fluid immiscible with water.
US Pat. No. 10,213,398

METHODS FOR ALLEVIATING STATIN MYOPATHY

1. A pharmaceutical formulation comprising a statin side effect-alleviating amount of ?-hydroxy ?-methylbutyrate (HMB), or a pharmaceutically acceptable salt thereof, in combination with:(a) 10 to 80 mg atorvastatin;
(b) 5 to 40 mg rosuvastatin;
(c) 10 to 80 mg pravastatin;
(d) 5 to 80 mg simvastatin;
(e) 10 to 80 mg lovastatin;
(f) 1 to 4 mg pitavastatin; or
(g) 20 to 80 mg fluvastatin;
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,214,678

COMPOSITIONS AND METHOD FOR TREATING OUT HYDROGEN SULFIDE AND PREVENTING SETTLING OF PRECIPITATE IN AN ENVIRONMENTALLY RESPONSIBLE DRILLING AND PACKER FLUID

Halliburton Energy Servic...

1. A fluid for use in the presence of hydrogen sulfide in a subterranean formation, comprising:an oleaginous base;
an additive comprising at least one ferrous based compound selected from the group of consisting of ferrous lactate, ferrous bis glycinate, ferrous citrate, ferrous acetate, ferrous fumarate, ferrous succinate, ferrous sacchrate, ferrous tartarate, ferrous glycine sulfate, ferrous glutamate, ferrous ascorbate, ferrous polymaltose, and combinations thereof; and
a viscosifier, such that the product of any reaction of the ferrous based compound with any hydrogen sulfide in the fluid will remain in suspension in the fluid.
US Pat. No. 10,213,399

COMPOSITIONS AND METHODS OF USE OF ?-HYDROXY-?-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY

Metabolic Technologies, I...

1. A method of modulating autophagy in a mammal comprising administering to the mammal from about 0.5 g to about 30 g of ?-hydroxy-?-methylbutyric acid (HMB), wherein upon said administration of said HMB to the mammal, autophagy is modulated in adipocytes.
US Pat. No. 10,214,426

OLIGOMERIZATION OF ETHYLENE TO LIQUID TRANSPORTATION FUELS WITH POST SYNTHESIS TREATED ZSM-5 CATALYST

Phillips 66 Company, Hou...

1. An oligomerization process to produce transportation fuels, the process comprising directing a feed stream comprising ethylene to a reactor that contains a fixed bed of ZSM-5 catalyst that is essentially free of catalyst metals other than silica and alumina, wherein the ZSM-5 catalyst is supported by an alumina binder, wherein prior to the oligomerization, the ZSM-5 catalyst is provided with a post synthesis treatment comprising a base wash to resist coke formation in the zeolite crystallites and extend catalyst life, wherein the oligomerization is conducted at a pressure between 0 psig and 800 psig, a temperature of between 260° C. and 420° C., and a gas hourly space velocity of between 1000 and 5000 inverse hours and wherein at least 85% of the ethylene is converted.
US Pat. No. 10,213,405

OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES

ALLERGAN, INC., Irvine, ...

1. A topical ophthalmic composition for the treatment of dry eye comprising:water;
a tonicity component selected from erythritol, carnitine, isomers thereof, and suitable salts thereof;
carboxymethyl cellulose or its suitable salt, or a combination of carboxymethylcellulose or its suitable salt and hyaluronic acid; and
glycerol;
wherein the composition is effective for the treatment of dry eye.
US Pat. No. 10,214,429

PHOSPHOR CONTAINING CE

Panasonic Intellectual Pr...

1. A phosphor comprising a crystal phase having a chemical composition CexM3-x-y?6?11-z, whereM is one or more elements selected from the group consisting of Sc, Y, La, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu;
? contains Si in an amount of 50 mol % or more of a total mol of ?;
? contains N in an amount of 80 mol % or more of a total mol of ?;
0 0?y?1.0; and
0?z?1.0, wherein
the phosphor shows:
a maximum peak of an emission spectrum in a wavelength range of 600 nm or more and 800 nm or less; and
a first peak of an excitation spectrum in a wavelength range of 500 nm or more and 600 nm or less.
US Pat. No. 10,214,688

METHOD FOR PRODUCING FLUORIDE FLUORESCENT MATERIAL

NICHIA CORPORATION, Anan...

1. A method for producing a fluoride fluorescent material, the method comprising mixing together a first solution containing at least first complex ions comprising tetravalent manganese and hydrogen fluoride, a second solution containing at least potassium ions and hydrogen fluoride and a third solution containing at least second complex ions comprising at least one element selected from the group consisting of elements belonging to Groups 4 and 14 of the Periodic Table and fluorine ions, whereinthe fluoride fluorescent material comprises a chemical composition represented by the following formula (I):
K2[M1?aMn4+aF6]  (I),
M is at least one element selected from the group consisting of elements belonging to Groups 4 and 14 of the Periodic Table, and a is a value that satisfies the relationship: 0 a minimum value of a weight median diameter of the fluoride fluorescent material is greater than or equal to 30 ?m.
US Pat. No. 10,212,897

SOYBEAN CULTIVAR S170001

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170001, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124453.
US Pat. No. 10,212,898

PLANTS WITH AN INTENSE FRUIT PHENOTYPE

NUNHEMS B.V., Nunhem (NL...

1. A Solanum lycopersicum plant or plant cell, tissue or plant part thereof comprising a reduced amount, activity or function of AGL11-like protein, wherein the AGL11-like protein has at least 95% amino acid sequence identity to SEQ ID NO: 3 wherein the plant does not have a deletion from nucleotide 1042 to nucleotide 637 upstream of the ATG start codon of SEQ ID NO: 1, and wherein the plant has an intense phenotype.
US Pat. No. 10,214,434

METHOD FOR THE TREATMENT OF METALS

Global Ecoprocess Service...

1. A method for precipitating metal waste in form of metal borates, wherein the waste which contains dissolved metal salts, is mixed with a boron compound, and the pH is adjusted to a value at which hydroxide precipitates of a first metal are formed to act as precipitation nuclei for formation of the metal borates, andwherein the pH is further adjusted to increase gradually for precipitating a second or further metals contained in the waste in form of metal borates.
US Pat. No. 10,212,899

SOYBEAN VARIETY 01062052

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 01062052, wherein a sample of seed of said variety has been deposited under ATCC Accession No. PTA-124995.
US Pat. No. 10,213,155

METHOD AND APPARATUS FOR PROCESSING USER LACTATE LEVEL INFORMATION

Nokia Technologies Oy, E...

1. A method, comprising:receiving, from a wearable sensor, current lactate level information of a user performing physical exercise;
setting, by the user, a target fatigue value for the physical exercise;
determining with a lactate level extraction and processing method target lactate level information based on the target fatigue value;
receiving characteristics of the physical exercise comprising information of an end exhaustion level of the physical exercise measured by lactate acid in a body of the user during the physical exercise;
determining adjusted characteristics comprising adjustments to at least one of a route and a speed of the physical exercise in order to match the current user lactate level information in the end of the physical exercise with the target lactate level information, based on the current lactate level information of the user, the target lactate level information and the characteristics for the physical exercise; and
outputting feedback comprising an indication of the adjusted characteristics of the physical exercise causing the user to adjust the at least one of a route and a speed of the physical exercise based on the adjusted characteristics.
US Pat. No. 10,213,411

USE OF PRODRUGS OF FUMARATES IN TREATING HEART FAILURE DISEASES

1. A method of treating heart failure with preserved ejection fraction in a subject having heart failure with preserved ejection fraction, the method comprising administering to the subject a therapeutically effective amount of one or more prodrugs of monomethyl fumarate or a pharmaceutically acceptable salt, polymorph, hydrate, solvate, or co-crystal thereof.
US Pat. No. 10,214,435

NON-EMULSIFIER FOR COMPLETION BRINES TO PREVENT EMULSION FROM FORMING

M-I L.L.C., Houston, TX ...

8. A method comprising:emplacing a wellbore fluid into a wellbore, the wellbore fluid comprising:
a base fluid;
one or more sorbitan esters;
one or more non-ionic surfactants; and
one or more amphoteric surfactants,
wherein the ratio of the one or more sorbitan esters to the one or more non-ionic surfactants to the one or more amphoteric surfactants is in the range of 1:2.5:1.6 to 1:5:3.
US Pat. No. 10,212,900

SWEET CORN HYBRID SVSC0111 AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A corn plant comprising at least a first set of the chromosomes of corn line SHW6S-14IW11, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124216.
US Pat. No. 10,212,901

SOYBEAN VARIETY 01068895

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068895, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124837.
US Pat. No. 10,212,902

SOYBEAN VARIETY 01067523

Monsanto Technology LLC, ...

1. A plant of soybean variety 01067523, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124979.
US Pat. No. 10,212,903

SOYBEAN VARIETY 5PFDE97

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PFDE97, representative seed of the variety having been deposited under ATCC Accession Number PTA-123780.
US Pat. No. 10,212,904

MAIZE INBRED PH42WT

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42WT, representative seed of the variety having been deposited under ATCC accession number PTA-124778.
US Pat. No. 10,212,905

MAIZE INBRED PH41DJ

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41DJ, representative seed of the variety having been deposited under ATCC accession number PTA-124810.
US Pat. No. 10,217,514

SEMICONDUCTOR MEMORY DEVICE

TOSHIBA MEMORY CORPORATIO...

1. An operation method for a semiconductor memory device,the device including:
a first electrode;
a second electrode; and
a memory cell provided between the first electrode and the second electrode, the memory cell including a resistance change film,
the method comprising:
when performing a writing operation for the memory cell to cause a resistive state of the memory cell to transition,
applying a first voltage of a first polarity to the first electrode;
applying a second voltage of a second polarity opposite from the first polarity to the second electrode; and
after the first voltage is applied to the first electrode, continuously applying a third voltage of the first polarity to the first electrode while the second voltage is applied to the second electrode,
the third voltage having an absolute value smaller than an absolute value of the first voltage.
US Pat. No. 10,212,906

MAIZE HYBRID X13M651

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X13M651, representative seed produced by crossing a first plant of variety PH41R5 with a second plant of variety PH2STM, wherein representative seed of the varieties PH41R5 and PH2STM have been deposited under ATCC Accession Numbers PTA-124793 and PTA-124413, respectively.
US Pat. No. 10,213,418

THERAPEUTIC USES OF BERBERINE FORMULATIONS

TWi Biotechnology, Inc., ...

1. A method of treating and/or preventing dermatologic toxicities induced by targeted therapy comprising topically administering to a subject in need thereof a pharmaceutically effective amount of a topical pharmaceutical composition comprising berberine, wherein said targeted therapy is selected from the group consisting of MEK inhibitors, HER2 inhibitors and mTOR inhibitors, and wherein berberine is the only pharmaceutically acceptable active component.
US Pat. No. 10,212,907

LETTUCE CULTIVAR LOCKWOOD

VANGUARD SEED, INC., Sal...

1. A seed of lettuce cultivar Lockwood, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-124028.
US Pat. No. 10,214,443

LITHIUM SILICATE MATERIALS

Ivoclar Vivadent AG, Sch...

1. A lithium silicate glass ceramic material formed by:a) heating a starting glass material which is essentially free of ZnO and comprises SiO2, LiO2, K2O, Al2O3, nucleating agent, and optionally Me(II)O, wherein Me is CaO, BaO, MgO, SrO or combinations thereof, at a first temperature of 500 to 600° C. such that nuclei suitable to form lithium metasilicate crystals are formed; and
b) heating the material formed after step a) at a second temperature of 680 to 720° C. to produce a lithium silicate glass ceramic which has lithium metasilicate as the main crystalline phase, and wherein the crystals are of lamellar or platelet form,
wherein the material formed after step b) is convertible to a lithium silicate glass ceramic having disilicate as the main crystalline phase by heating to a third temperature which is higher than the second temperature.
US Pat. No. 10,212,908

MALE STERILITY IN CATHARANTHUS

BALL HORTICULTURAL COMPAN...

1. A Catharanthus roseus plant comprising a nuclear recessive allele, wherein the nuclear recessive allele confers male-sterility, wherein Catharanthus roseus line P7998D comprises the nuclear recessive allele, and wherein representative seed of Catharanthus roseus line P7998D has been deposited under ATCC Accession No. PTA-122493.
US Pat. No. 10,214,700

METHODS UTILIZING DURABLE FUNCTIONAL MATERIALS FOR CHEMICAL PROCESSES THAT INCLUDE AN OXIDATION STEP

Arizona Board of Regents ...

1. A method, comprisingcontacting a redox active oxygen carrier material with a fluid stream to reduce a redox active metal oxide in the redox active oxygen carrier material and oxidize a component in the fluid stream; and
contacting the redox active oxygen carrier material with a second fluid stream to oxidize the reduced redox active metal;
wherein redox active oxygen carrier material comprises a redox active metal ion atomically dispersed in a zirconia or yttria-stabilized zirconia matrix.
US Pat. No. 10,212,909

ARTICHOKE VARIETY NUN 04455 ARA

NUNHEMS B.V., Nunhem (NL...

1. A hybrid plant, plant part or seed of Artichoke variety NUN 04455 ARA, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 42843.
US Pat. No. 10,212,910

SOYBEAN VARIETY 5PVGJ25

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PVGJ25, representative seed of the variety having been deposited under ATCC Accession Number PTA-125068.
US Pat. No. 10,213,422

COMPOSITIONS AND METHODS OF INHIBITING HISTONE DEACETYLASES

Yale University, New Hav...

1. A method for treating pulmonary hypertension in a subject in need thereof comprising administering to the subject a composition comprising tasquinimod or a salt or solvate thereof.
US Pat. No. 10,212,911

ENDOPHYTES, ASSOCIATED COMPOSITIONS, AND METHODS OF USE THEREOF

Indigo Agriculture, Inc.,...

1. A synthetic combination comprising a purified microbial population in association with a plurality of seeds or seedlings of an agricultural plant, wherein the purified microbial population comprises a first endophyte capable of production of acetoin, wherein the first endophyte is of the genus Cladosporium and comprises an ITS rRNA nucleic acid sequence comprising SEQ ID NO: 3694, and wherein the first endophyte is present in the synthetic combination in an amount effective to provide a benefit to the seeds or seedlings or the plants derived from the seeds or seedlings.
US Pat. No. 10,214,703

LUBRICANTS WITH ZINC DIALKYL DITHIOPHOSPHATE AND THEIR USE IN BOOSTED INTERNAL COMBUSTION ENGINES

AFTON CHEMICAL CORPORATIO...

1. An engine oil composition for use in a boosted internal combustion engine, said engine oil composition comprising:greater than 50 wt. % of a base oil of lubricating viscosity; and
an additive composition comprising:
one or more overbased calcium-containing detergents having a total base number of greater than 225 mg KOH/g, measured by the method of ASTM D-2896, and
one or more zinc dialkyl dithiophosphate compounds, wherein the one or more zinc dialkyl dithiophosphate compounds are derived from a molar ratio of secondary alcohol to primary alcohol of from 0:100 to 100:0, and have an average total carbon content of 12 to 15 moles of carbon atoms per mole of phosphorus,
the engine oil composition includes an amount of the overbased calcium-containing detergent that provides 1100 ppm by weight to less than 1800 ppm by weight of calcium to the engine oil composition, and 0.01 wt. % to 5 wt % of the zinc dialkyl dithiophosphate, both amounts being based on a total weight of the engine oil composition, and
the engine oil composition contains 0.085 wt. % or less of phosphorus, based on a total weight of the engine oil composition, and
the engine oil composition contains a sufficient amount of an oil soluble molybdenum compound to provide 5 ppm by weight to 300 ppm by weight of molybdenum to the engine oil composition, based on a total weight of the engine oil composition, and
where the engine oil composition comprises not more than 10 wt % of a Group IV base oil, a Group V base oil or a combination thereof.
US Pat. No. 10,218,034

ELECTROLYTE FOR SODIUM SECONDARY BATTERY AND SODIUM SECONDARY BATTERY USING THEREOF

SK INNOVATION CO., LTD., ...

1. A sodium secondary battery having an operation temperature of 120° C. to 200° C. and comprising:a cathode containing a transition metal, and impregnated in an electrolyte having a melting point of 150° C. or less and comprising a molten sodium salt and an electrolyte additive made of an inorganic sodium salt represented by the following Chemical Formula:
NaxA
wherein A is at least one anion selected from the group consisting of SaOb2? (1?a<4, 1 x is an integer of 1 to selected depending on an ionic valence of A which is a counter ion;
an anode containing sodium; and
a sodium ion conductive solid electrolyte provided between the cathode and the anode.
US Pat. No. 10,212,912

ENDOPHYTIC MICROBIAL SYMBIONTS IN PLANT PRENATAL CARE

University of Saskatchewa...

1. A plant seed manually or mechanically coated with at least one endophyte, wherein the plant is not wheat and the endophyte is selected from the group consisting of a Streptomyces sp. strain or culture thereof which is deposited under IDAC 081111-06 or which comprises the 16S rDNA sequence as shown in SEQ ID NO:6; a Paraconiothyrium sp. strain or culture thereof which is deposited as IDAC 081111-03 or which comprises the ITS rDNA sequence as shown in SEQ ID NO:5; a Pseudeurotium sp. or culture thereof which is deposited under IDAC 081111-02 or which comprises the ITS rDNA sequence as shown in SEQ ID NO:4; a Penicillium sp. or culture thereof which is deposited under IDAC 081111-01 or which comprises the ITS rDNA sequence as shown in SEQ ID NO:3; a Cladosporium sp. or culture thereof which is deposited under IDAC 200312-06 or which comprises the ITS rDNA sequence as shown in SEQ ID NO:1; and a Cladosporium sp. or culture thereof which is deposited under IDAC 200312-05 or which comprises the ITS rDNA sequence as shown in SEQ ID NO:2.
US Pat. No. 10,213,425

ROLE OF N-2-HYDROXY-ETHYL-PIPERAZINE-N?-2-ETHANE SULFONIC ACID (HEPES) IN PAIN CONTROL AND REVERSAL OF DEMYELINIZATION INJURY

BESPOKE BIOSCIENCE, LLC, ...

1. A method of treating pain and post-chemotherapy cognitive impairment caused by demyelination in a human subject following a treatment for a cancer comprising the steps of:identifying a human subject in need for treatment against the pain post-chemotherapy cognitive impairment caused by demyelination following a treatment for the cancer; and
administering a pharmaceutical composition comprising N-2-hydroxy-ethyl-piperazine-N?-2-ethane sulfonic acid (HEPES) and derivatives thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers once daily at a dosage of 10-100 mg/kg of body weight, wherein the pharmaceutical composition is administered orally, subcutaneously, parenterally, intravenously, peritoneally, or intramuscularly that is sufficient to treat the pain and post-chemotherapy cognitive impairment caused by demyelination.
US Pat. No. 10,213,426

METHOD OF OPTIMIZING CONDITIONS FOR SELECTIVELY REMOVING A PLURALITY OF SENESCENT CELLS FROM A TISSUE OR A MIXED CELL POPULATION

UNITY BIOTECHNOLOGY, INC....

1. A method for treating a subject to relieve or delay progression of symptoms of a disease or disorder by selectively removing p16 positive senescent cells that are not cancer cells from a target tissue in the subject,wherein the method comprising the following steps:
(a) performing a physical examination of the subject to determine a target tissue in the subject from which it is desirable to remove senescent cells that are not cancer cells;
(b) identifying a small molecule compound that is capable of selectively removing senescent cells from the target tissue;
(c) determining a course of treatment that includes a dosage, a formulation, and a route of administration of the small molecule compound that selectively kills senescent cells in the target tissue, compared with non-senescent cells;
(d) administering the small molecule compound identified in step (b) to the subject in accordance with the course of treatment determined in step (c); and
(e) withholding treatment of the subject with the small molecule during a non-treatment interval of at least two weeks that immediately follows the administering in step (d);
whereby at least some of the senescent cells are selectively removed from the target tissue consequent to step (d), resulting in relief or delayed progression of at least one of the symptoms of the disease or disorder during the non-treatment interval of step (e).
US Pat. No. 10,214,450

HARDENER COMPOSITION FOR ADDITION-POLYMERISATION-BASED SYNTHETIC FIXING MORTAR SYSTEMS, AND THE USE AND PRODUCTION THEREOF

1. A method for fixing anchoring elements in a hole or crevice, in which a synthetic fixing mortar system and an anchoring means are introduced successively or substantially simultaneously into the hole or crevice in a substrate, wherein said synthetic fixing mortar system is hardenable by addition polymerisation and includes a hardener composition and a hardenable epoxy- and/or isocyanate-based reactive synthetic resin, wherein said hardener composition includes oligomeric siloxanes having on average per molecule at least one organic radical that carries one or more secondary and/or primary amino and/or thiol groups and having on average per molecule one or more hydrolysable groups, and optionally one or more additives.
US Pat. No. 10,214,451

CEMENT AND SKINNING MATERIAL BASED ON A WATER-SWELLABLE CLAY, AND METHOD FOR PRODUCING SEGMENTED OR SKINNED CERAMIC HONEYCOMB STRUCTURES

DOW GLOBAL TECHNOLOGIES L...

1. An uncured inorganic cement composition comprising:a) 1 to 18% by weight of a water-swellable clay;
b) 20 to 70% by weight of non-water-swellable, non-fugitive, inorganic filler particles that have an equivalent diameter of greater than 250 nm;
c) 20 to 60% by weight of water;
d) larger than to less than 0.05% by weight of a water-soluble cellulosic polymer;
e) Larger than 0 to less than 0.25% by weight of inorganic particles having an equivalent diameter of 250 nm or less; and
f) 5 to 30% by weight of one or more porogens;
wherein the uncured cement composition is self-supporting with a shear viscosity of 1 to less than 28 Pa*s when measured by oscillating shear rheometry methods at 20° C., 1 rad/s oscillation and 5 MPa amplitude.
US Pat. No. 10,214,452

GEOPOLYMER FOAM FORMULATION FOR A NON-FLAMMABLE, SOUND-ABSORBING, THERMALLY INSULATING GEOPOLYMER FOAM ELEMENT

1. A geopolymer foam formulation comprising:at least one inorganic binder which includes blast furnace slag, and also microsilica and/or metakaolin;
at least one alkaline activator selected from the group consisting of alkali metal hydroxides, alkali metal carbonates, alkali metal aluminates, alkali metal silicates and mixtures thereof;
at least one alkyl polyglucoside surfactant;
a gas phase and
water.
US Pat. No. 10,214,708

LIQUID DETERGENTS COMPRISING MICROFIBROUS CELLULOSE AND METHODS OF MAKING THE SAME

CP KELCO U.S., INC., Atl...

1. A liquid detergent comprising:an aqueous detergent composition comprising a surfactant system that comprises,
a microfibrous cellulose present in the aqueous detergent composition at a concentration from about 0.05% to about 1.0% (w/w),
an anionic surfactant present in the aqueous detergent composition at a concentration from about 5% to about 20% (w/w active surfactant),
a suspended particulate, and
a salt.
US Pat. No. 10,214,453

ADVANCED CEMENT FREE COMPOSITION FOR CONCRETE AND PANELS AND METHOD OF PREPARATION THEREOF

1. A cement free composition useful for preparation of concrete cubes and panels comprising; 40-50 w % sea sand; 15-20 w % sea water; 8-12 w % Sodium hydroxide; 4-10 w % Sodium meta silicate and 15-21w % Fly ash.
US Pat. No. 10,214,709

OXYGEN-BASED CLEANING COMPOSITION COMPRISING A SAPONIN LAYER

1. An oxygen-based cleaning composition, comprising a cleaning formulation in powder form, wherein the cleaning formulation includes;a) a layer comprising a hydrogen peroxide addition compound powder for producing hydrogen peroxide;
b) a surfactant layer formed by coating an outer surface of the hydrogen peroxide addition compound layer with a liquid surfactant;
c) a saponin layer formed by coating an outer surface of the surfactant layer with a saponin powder; and
d) a sodium bicarbonate layer formed by coating an outer surface of the saponin layer with a sodium bicarbonate powder, wherein the cleaning formulation comprises, based on 100 parts by weight of the hydrogen peroxide addition compound, 8 to 13 parts by weight of the surfactant, 0.5 to 2 parts by weight of saponin, and 4 to 8 parts by weight of sodium bicarbonate.
US Pat. No. 10,213,431

PRESERVATIVE FREE BRIMONIDINE AND TIMOLOL SOLUTIONS

Allergan, Inc., Irvine, ...

1. A preservative free brimonidine and timolol composition for lowering intraocular pressure in a human patient comprising the following formulation: about 0.2% w/v brimonidine tartrate; about 0.5% w/v timolol; about 2.15% w/v sodium phosphate dibasic heptahydrate; water and at a pH of about 6.9.
US Pat. No. 10,213,432

DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR

NOVARTIS AG, Basel (CH)

1. A method of treating breast cancer in a human patient in need of such treatment, comprising administering to said human patient a compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof in a therapeutically effective amount of about 60 to about 120 mg daily for five consecutive days in any seven day period, wherein said compound is administered to the patient each day for five consecutive days and then not administered to the patient for two consecutive days before at least one further dose of said compound is administered to the patient wherein the compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof is administered in combination with letrozole.
US Pat. No. 10,213,434

USE OF FACTOR XA INHIBITORS FOR REGULATING GLYCEMIA

VAIOMER, Labege (FR)

1. A method for regulating glycemia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a factor Xa inhibitor, wherein said factor Xa inhibitor is a direct inhibitor of factor Xa activity and/or an inhibitor of factor Xa expression.
US Pat. No. 10,212,923

HUMANIZED DIPEPTIDYL-PEPTIDASE IV (DPP4) ANIMALS

REGENERON PHARMACEUTICALS...

1. A humanized rodent embryo comprising a replacement of a genomic fragment comprising at least one exon of an endogenous rodent Dpp4 gene at an endogenous rodent Dpp4 locus with a genomic fragment comprising at least one exon of a human DPP4 gene to form a modified DPP4 gene at the endogenous rodent Dpp4 locus, wherein expression of the modified DPP4 gene is under control of rodent regulatory elements at the endogenous rodent Dpp4 locus, and wherein the rodent is a mouse or a rat.
US Pat. No. 10,213,436

METHODS OF TREATING CANCER USING AURORA KINASE INHIBITORS

Millennium Pharmaceutical...

1. A method of treating small-cell lung cancer in a subject in need thereof, consisting of administering to the subject on a 28-day dose schedule a twice-daily dose of an Aurora A kinase inhibitor, wherein the Aurora A kinase inhibitor is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-m ethoxybenzoic acid, or a pharmaceutically acceptable salt thereof, in combination with a once-weekly dose of paclitaxel, whereinthe administered twice-daily dose of the Aurora A kinase inhibitor is about 30 mg, about 35 mg, about 40 mg, or about 45 mg, and is administered on days 1-3, 8-10, and 15-17 of the 28-day schedule; and
the administered once-weekly dose of paclitaxel is from about 40 mg/m2 to about 80 mg/m2, and is administered on days 1, 8, and 15 of the 28-day schedule.
US Pat. No. 10,219,328

ALKALI-FREE ALUMINOSILICATE GLASSES, SUITABLE AS SUBSTRATE FOR INDUCTION HEATING COOKTOPS APPLICATIONS

EUROKERA, Chateau-Thierr...

1. A non-crystalline aluminosilicate glass whose composition is free, with the exception of inevitable traces, of alkali metals and contains, expressed as a weight percentage of oxides:60 to 70% SiO2
13 to 22% Al2O3
0 to 9% B2O3
1 to 6% MgO
0 to 5% CaO
1 to 5% BaO
2 to 12% ZnO, and
0 to 3% SrO;whereinAl2O3+B2O3+ZnO>23%, and
B2O3+MgO?CaO?BaO?SrO<6%, wherein the composition is free of TiO2.
US Pat. No. 10,213,437

PHARMACEUTICAL PREPARATION FOR MASKED TASTE ORAL ADMINISTRATION, CONTAINING CLOMIPRAMINE

CTC BIO, INC., Seoul (KR...

1. A method for manufacturing a pharmaceutical preparation for oral administration comprising clomipramine as a sole active ingredient comprising:adding a cation exchange resin and an anion polymer to a liquid melt of clomipramine hydrochloride and stirring for at least 1 hour.
US Pat. No. 10,214,462

OLIGOMERIZATION OF ETHYLENE TO LIQUID TRANSPORTATION FUELS WITH POST SYNTHESIS TREATED ZSM-5 CATALYST

Phillips 66 Company, Hou...

1. An oligomerization process to produce transportation fuels, the process comprising directing a feed stream comprising ethylene to a reactor that contains a fixed bed of ZSM-5 catalyst that is essentially free of catalyst metals other than silica and alumina, wherein the ZSM-5 catalyst is supported by an alumina binder, wherein prior to the oligomerization, the ZSM-5 catalyst is provided with a post synthesis treatment comprising an acid wash to resist coke formation in the zeolite crystallites and extend catalyst life, wherein the oligomerization is conducted at a pressure between 0 psig and 800 psig, a temperature of between 260° C. and 420° C., and a gas hourly space velocity of between 1000 and 5000 inverse hours and wherein at least 85% of the ethylene is converted.
US Pat. No. 10,213,439

THERAPEUTIC AND METHOD OF USE

Predictive Therapeutics, ...

1. A pill or pellet consisting essentially of cannabis, human serum albumin, a compound selected from the group consisting of ibuprofen, naproxen, and a combination thereof, and a compound selected from the group consisting of progestin, progesterone, and a combination thereof.
US Pat. No. 10,214,719

METHOD OF CULTURING ANTRODIA CINNAMOMEA WITH HIGH TRITERPENOIDS

Ultra-Microrigin Biomedic...

1. A method of culturing Antrodia cinnamomea with high triterpenoids, comprising the steps of:preparing a culture medium (nutrient precursor): mixing a malt extract, glucose, peptone, agar, and a mushroom's extract with distilled water to obtain a culture medium, the culture medium includes 1%-2% w/v of the malt extract, 1%-2% w/v of the glucose, 0.1%-0.2% w/v of the peptone, 1%-2% w/v of the agar, and 0.1%-0.2% w/v of a concentrated solution of mushroom extract, wherein, the mushroom extract is the concentrated solution of Flammulina velutipes, Auricularia auricular-judae, Tremella fuciformis, or Lentinus edodes;
sterilization: placing the culture medium in a high-pressure sterilization machine for sterilization in a pressure of 1 kg/cm2, and 120° C-121° C. for 25-30 minutes to obtain a sterilized culture medium;
forming a solidified culture medium by: placing the sterilized culture medium in an incubator in a disinfection environment to cool the sterilized culture medium and to obtain a solidified culture medium after a predetermined time;
transplanting Antrodia cinnamomea strains : transplanting Antrodia cinnamomea strains, wherein are transplanted at a top, a bottom, a right, a left, and a center of the solidified culture medium, and an separated interval between the neighboring strains; and
exposing under a specific beam, wherein: exposing the solidified culture medium to red light with a wavelength of 620-625 nm and an illuminance of 400-600 Lux for thirty days in 25° C-30° C;
thereby, exposure under the red light and stimulation of the nutrient precursor increases the production of triterpenoids in the fruiting bodies of Antrodia cinnamomeas.
US Pat. No. 10,215,743

INTRODUCING PERIODICITY FOR DISCRETE DETERMINATION OF CONCENTRATIONS OF GASES IN A GASEOUS MIXTURE

1. A device for detecting a concentration of a component of a gaseous sample, the device comprising:a trapping chamber for temporarily containing a volume of the sample;
a sensing chamber proximate to the trapping chamber and capable of being coupled with the trapping chamber so as to receive a portion of the sample from the trapping chamber during operation of the device;
a valve separating the sensing chamber from the trapping chamber;
a pump coupled with the trapping chamber, and wherein the pump is configured to pressurize the gaseous sample in the trapping chamber;
a control unit in communication with the valve so as to control via operation of the valve introduction of gaseous sample into the sensing chamber, and wherein the control unit is in communication with the pump so as to control a pressure of the gaseous sample, and wherein the control unit is programmed with instructions to introduce periodicity by introducing changes through at least one of the valve and the pump;
a power supply to provide electrical current to components of the device; a sensor in electronic communication with the power supply, and wherein the sensor includes a sensing surface, and wherein the sensor surface is exposed to the inside of the sensing chamber, and wherein the sensor is in electronic communication with the power supply; and
a memory in electronic communication with the power supply, and wherein the memory is configured with instructions that cause the device to:
make a computation related to Mathieu's Equation with a value for each initial condition of such equation to determine when a value associated with an electrical change in the sensor is in a stable domain, wherein a stable domain is a numeric domain where values can be predicted in accordance with the said Mathieu's Equation, and wherein an unstable domain is a numeric domain where a resulting value is unreliable; and
when the value associated with the electrical change is in a stable domain, determine a numerical value associated with the concentration of the component in the sample based on an electrical characteristic of the sensor.
US Pat. No. 10,213,440

ORAL TRANSMUCOSAL PHARMACEUTICAL COMPOSITIONS INCLUDING TESTOSTERONE AND AN AROMATASE INHIBITOR

PROFESSIONAL COMPOUNDING ...

1. A method comprising:measuring a first blood serum concentration of testosterone and estradiol of a male patient;
formulating a composition consisting of a mucosal penetration enhancer, a sugar, a solvent, and active pharmaceutical ingredients (APIs) consisting of anastrozole and testosterone present in amounts intended to restore the testosterone level of the patient to a physiologic range based on a deficiency determined from the first measured blood serum concentration of testosterone and anastrozole; and
delivering the composition to an oral mucosal lining of the patient for a sufficient amount of time for diffusing said APIs through the mucosal lining of the oral cavity and into the bloodstream of the patient.
US Pat. No. 10,213,441

MEDICINAL COSMETIC LIPOATROPHY

1. A method of causing fat cell atrophy to decrease the size of a small fat deposit comprising the steps of:identifying a small fat deposit of an individual to be decreased; and
administering, to the individual, an injectable composition comprising a corticosteroid, in the amount sufficient to cause a decrease in the size of the small fat deposit;
wherein the step of administering comprises injecting a sufficient amount of the composition, using a needle, into the small fat deposit of the individual, to cause a decrease in the size of the small fat deposit;
wherein the composition comprises between 1 to 9 mg of Triamcinolone acetonide as the corticosteroid in a physiologically and pharmaceutically acceptable vehicle; and
wherein the injectable composition comprises no vasoconstrictor agent.
US Pat. No. 10,214,465

PROCESSES FOR INCREASING THE OVERALL AROMATICS AND XYLENES YIELD IN AN AROMATICS COMPLEX

UOP LLC, Des Plaines, IL...

1. A process for increasing overall xylenes yield in an aromatics complex, the process comprising the steps of:separating an aromatics-rich reformate into a first hydrocarbon stream comprising C7? hydrocarbons, a second hydrocarbon stream comprising C8-C10 aromatics, and a third hydrocarbon stream comprising C10+ aromatics;
isomerizing the second hydrocarbon stream comprising C8-C10 aromatics to produce a C8-C10 isomerization product stream;
passing the C8-C10 isomerization product stream to a napthene dehydrogenation zone to produce a napthene dehydrogenation zone product stream;
separating the napthene dehydrogenation zone product stream into a first napthene dehydrogenation zone product stream comprising C7? hydrocarbons and a second naphthene dehydrogenation zone product stream comprising C8+ aromatics; and
passing the second napthene dehydrogenation zone product stream comprising C8+ aromatics to a xylenes recovery section or transalkylation zone.
US Pat. No. 10,214,721

METHOD FOR MAKING CULTURE MEDIUM

Tsinghua University, Bei...

1. A method for making a culture medium for culturing neural cells, each neural cell comprising a neural cell body and neurite branched from the neural cell body, the method comprising:providing an original carbon nanotube structure comprising a drawn carbon nanotube film comprising a plurality of carbon nanotubes that are joined end to end by van der Waals force and are substantially oriented along the same direction;
forming a carbon nanotube structure comprising a plurality of carbon nanotube wires spaced from each other by treating the original carbon nanotube structure, wherein a distance between adjacent two of the plurality of carbon nanotube wires is greater than or equal to a diameter of the neural cell body, the plurality of carbon nanotube wires are capable of guiding extending directions of the neurites; and the treating the original carbon nanotube structure comprises:
forming a suspended original carbon nanotube structure;
atomizing a solvent into a plurality of liquid drops, a diameter of each of the plurality of liquid drops is less than or equal to 10 micrometers;
spraying the plurality of liquid drops into a surface of the suspended original carbon nanotube structure, using a flowing gas, to soak the suspended original carbon nanotube structure; and
evaporating the plurality of liquid drops from the suspended original carbon nanotube structure to form the plurality of carbon nanotube wires, wherein a diameter of each of the plurality of carbon nanotube wires is greater than or equal to 1 micrometer and less than or equal to 10 micrometers, the distance between adjacent carbon nanotube wires is greater than or equal to 20 micrometers and less than or equal to 100 micrometers;
fixing the carbon nanotube structure on a substrate; and
forming a polar surface on the carbon nanotube structure using poly-D-lysine or polyetherimide.
US Pat. No. 10,212,930

GREASE-LIKE GEL FOR REPELLING INSECTS AND PREVENTING UNDESIRABLE BEHAVIOR IN HOOFED ANIMALS

Pacific Tech Industries, ...

1. An insect or hoofed animal repelling composition, comprising:70 to 95 wt. % of a base oil selected from the group consisting of white oil, polyalphaolefins, glycols, polyalkylene glycols, alkylated naphthalenes, alkylated benzenes, esters and combinations thereof;
3 to 20 wt. % of a thickening agent;
2.0 to 20.0 wt. % of a tackifying polymer selected from the group consisting of polybutene, polyalphaolefin, ethylene/propylene copolymer, methacrylate, polyisobutylene, and combinations thereof;
0.005 to 0.5 wt. % of a repellent agent selected from the group consisting of capsaicin, piperine, allyl isothiocyanate, allicin, and combinations thereof; and
0.25 to 5 wt. % of a solubility improving additive.
US Pat. No. 10,214,722

METHODS FOR EXPANDING AND MAINTAINING HUMAN PLURIPOTENT STEM CELLS (PSCS) IN AN UNDIFFERENTIATED STATE IN A SINGLE CELL SUSPENSION CULTURE

1. A method of expanding and maintaining human pluripotent stem cells (PSCs) in an undifferentiated state in a single cell suspension culture, the method comprising:(a) passaging the human PSCs in a suspension culture by mechanical dissociation of PSC clumps to single cells for at least 2 and no more than 10 passages, to thereby obtain a suspension culture of human PSCs devoid of clumps, and subsequently;
(b) passaging said suspension culture of human PSCs devoid of said clumps,
thereby expanding and maintaining the human PSCs in the undifferentiated state in the single cell suspension culture, wherein the cells of step (a) and cells of step (b) are passaged for at least a total of 15 passages and cultured for at least a month in a culture medium which comprises (i) interleukin 11 (IL11) and Ciliary Neurotrophic Factor (CNTF); (ii) basic fibroblast growth factor (bFGF) and the IL6RIL6 chimera; (iii) a soluble interleukin 6 (IL6) receptor and a gp130 agonist; or (iv) interleukin 11 (IL11) and oncostatin, and wherein following step (b) at least 50% of said human pluripotent stem cells are characterized by an OCT4+/TRA1-60?/TRA1-81?/SSEA1+/SSEA4? expression signature.
US Pat. No. 10,215,746

METHODS FOR DIAGNOSIS AND INTERVENTION OF HEPATIC DISORDERS

The Regents of the Univer...

1. A kit of components for determining one or both of cholate clearance and cholate shunt in a subject with, or suspected of having or developing, a hepatic disorder; the kit comprisinga first component comprising one or more vials, each vial comprising a single intravenous dose of a first distinguishable cholate compound in aqueous sodium bicarbonate solution;
a second component comprising one or more vials, each vial comprising a single oral dose of a second distinguishable cholate compound;
a third component comprising a plurality of sample collection tubes and/or transport vials;
a fourth component comprising a suitable container means; and
a fifth component comprising one or more vials, each vial comprising a quantity of human albumin for mixing with the single intravenous dose of the first distinguishable cholate compound prior to intravenous administration.
US Pat. No. 10,213,443

TETRACYCLINE TOPICAL FORMULATIONS, PREPARATION AND USES THEREOF IN TREATING AN OCULAR CONDITION

Hovione Scientia Limited,...

1. A method of treating an ophthalmic condition amenable to treatment by a tetracycline, the method comprising:topically applying to the ocular tissue of a patient in need thereof a topical tetracycline suspension, the topical tetracycline suspension comprising:
a tetracycline, or a pharmaceutically acceptable salt, hydrate, or polymorph thereof in a suspended form within the formulation;
a liquid medium which dissolves less than 5% of the active ingredient from the class of tetracyclines determined by HPLC at room temperature after 2 hours and comprises mineral oil; and
a polymeric hydrocarbon gelling agent,
wherein the tetracycline has a D90 particle size that is from about 4 microns to about 10 microns.
US Pat. No. 10,214,723

GENE EDITING IN THE OOCYTE BY CAS9 NUCLEASES

1. A method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte:(a) a mRNA encoding a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein); and
(b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA); or
(b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA;
wherein the mRNA encoding the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) are introduced into both the nucleus/pronucleus and the cytoplasm of said oocyte; and
wherein the Cas9 protein encoded by the Cas9 mRNA introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
US Pat. No. 10,213,444

COMPOSITION AND METHOD FOR TREATING BIPOLAR DISORDER

Laureate Institute For Br...

1. A method for treating bipolar depression in an individual comprising:delivering, as a single drug delivery system, to an individual with bipolar depression a pharmacologically effective amount of a compound capable of inhibiting a COX-1enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain.
US Pat. No. 10,214,468

METHOD FOR CO-PRODUCTION OF 1-CHLORO-3,3,3-TRIFLUOROPROPENE, 2,3,3,3-TETRAFLUOROPROPENE AND 1,3,3,3-TETRAFLUOROPROPENE

Zhejiang Quzhou Juxin Flu...

1. A method for co-production of 1-chloro-3,3,3-trifluoropropene, 2,3,3,3-tetrafluoropropene and 1,3,3,3-tetrafluoropropene, the method comprising:(a) preheating and then directing hydrogen fluoride and 1,1,1,3,3-pentachloropropane into a first reactor in a molar ratio of 9:1-15:1, wherein the first reactor comprises an upper section filled with an aluminum oxide supported chromium metal catalyst and a lower section filled with a chromic oxide supported indium metal catalyst, wherein the hydrogen fluoride and the 1,1,1,3,3-pentachloropropane are reacted in the upper section of the first reactor at a temperature of 200-400° C. and at an air flow rate of 300-1,000 h?1, and a product from the upper section enters the lower section of the first reactor to continuously react with the 1,1,2,3-tetrachloropropane to obtain a first reaction product of the first reactor, wherein a molar ratio of the 1,1,2,3-tetrachloropropane to the hydrogen fluoride in the lower section of the first reactor is 3:9-5:9;
(b) directly directing the first reaction product of the first reactor into a second reactor to perform a reaction catalysed by a catalyst at a temperature of 250-450° C. and at an air flow rate of 500-1,500 h?1 to obtain a second reaction product of the second reactor;
(c) separating the second reaction product of the second reactor in a hydrogen chloride tower to obtain a first tower bottom fraction and a first tower top fraction, which is hydrogen chloride that is refined to obtain hydrochloric acid;
(d) removing hydrogen fluoride and hydrogen chloride from the first tower bottom fraction of the hydrogen chloride tower by sequentially passing the first tower bottom fraction through a water washing tower, an alkaline washing tower and a drying tower to obtain a substance;
(e) directing the substance into a first rectifying tower to obtain a second tower bottom fraction and a second tower top fraction;
(f) directing the second tower bottom fraction of the first rectifying tower into a second rectifying tower to obtain 1-chloro-3,3,3-trifluoropropene and a third tower top fraction; and
(g) directing the second tower top fraction of the first rectifying tower into a third rectifying tower to obtain 2,3,3,3-tetrafluoropropene at the top of the third rectifying tower and 1,3,3,3-tetrafluoropropene at the bottom of the third rectifying tower.
US Pat. No. 10,214,724

METHODS FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO BRAIN MICROVASCULAR ENDOTHELIAL CELLS

Wisconsin Alumni Research...

1. A method for generating a population of human brain microvascular endothelial cells (BMECs) from human pluripotent stem cells, wherein the method comprises, in order,(a) culturing human pluripotent stem cells for about 24 hours in a chemically defined, serum-free culture medium that comprises an activator of Wnt/?-catenin signaling, whereby cells that express mesodermal markers are obtained;
(b) culturing the cells expressing mesodermal markers for about 5 days in the presence of a chemically defined, serum-free culture medium comprising a neuronal cell culture supplement, whereby cells that express endothelial progenitor marker Flk-1 are obtained; and
(c) culturing the Flk-1+ cells of (b) for about two days in the presence of a chemically defined, serum-free endothelial medium comprising a neuronal cell culture supplement, bFGF/FGF2, and retinoic acid (RA), whereby a cell population comprising human BMECs is obtained.
US Pat. No. 10,217,541

AMORPHOUS POLYCARBONATE FILMS FOR CAPACITORS, METHODS OF MANUFACTURE, AND ARTICLES MANUFACTURED THEREFROM

SABIC GLOBAL TECHNOLOGIES...

1. A film comprising a copolycarbonate, whereinthe film is a uniaxially-stretched, extruded film comprising at least one film region having:
an average thickness of more than 0 and less than 14 micrometers with a standard deviation of 0.8 micrometer to 1.6 micrometers,
a surface having a surface roughness average of less than 0.04 micrometer as measured by optical profilometry,
a dielectric constant at 1 kHz and room temperature of at least 2.7,
a dissipation factor at 1 kHz and room temperature of 1% or less, and
a breakdown strength of at least 620 Volt/micrometer; and
the copolycarbonate has a Tg of greater than 180° C. and comprises carbonate units derived from polymerization of 2,2-bis(4-hydroxyphenyl) propane and 2-phenyl-3,3-bis(4-hydroxyphenyl) phthalimidine.
US Pat. No. 10,212,933

LOW VOLATILITY HERBICIDAL COMPOSITIONS

1. A herbicidal composition concentrate comprising:dicamba, or an agriculturally acceptable salt or ester thereof; and
a potassium or sodium monocarboxylate of a monocarboxylic acid;
wherein:
the concentrate comprises an amount of the potassium or sodium monocarboxylate sufficient to reduce the concentration of volatilized dicamba in the vapor phase surrounding a diluted version of the concentrate relative to the concentration of volatilized dicamba in the vapor phase surrounding an otherwise identical diluted version of the concentrate lacking the potassium or sodium monocarboxylate.
US Pat. No. 10,216,005

METHOD FOR OPTIMIZING A MEASURED CONTOUR OF A SPECTACLE FRAME

Essilor International, C...

1. A method implemented by computer means for optimizing a measured contour of an opening of a spectacle frame, the method comprising:a contour data providing step (S1), during which a contour data representing measured points of a contour of the spectacle frame is provided,
a working contour defining step (S2), during which a working contour of the spectacle frame is defined,
a first contour cost function providing step (S3), during which a first contour cost function is provided, the first contour cost function being a function of the mth derivative of the curve of at least a portion of the working contour with m an integer greater than or equal to 2,
a set of contour cost functions providing step (S4), during which a set of contour cost functions is provided, each contour cost function of the set of contour cost functions being a function of at least the deviation between the working contour and the measured points of the contour and the set of contour cost functions comprising at least one contour cost function,
a global contour cost function evaluation step (S5), during which a global contour cost function is evaluated, the global contour cost function being a weighted sum of the first contour cost function and of each contour cost function of the set of contour cost functions,
a contour modifying step (S6), during which the working contour is modified,
wherein the global contour cost function evaluation and contour modifying steps are repeated so as to minimize the global contour cost function.
US Pat. No. 10,212,934

PESTICIDAL COMPOSITIONS

BASF Agro B.V., Arnhem (...

1. A composition comprising,1) as component I a compound selected from:
compound I-1 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)pent-3-yn-2-ol;
compound I-2 1-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-cyclopropyl-2-(1,2,4-triazol-1-yl)ethanol;
compound I-3 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-4 1-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-cyclopropyl-2-(1,2,4-triazol-1-yl)ethanol;
compound I-5 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-3-methyl-1-(1,2,4-triazol-1-yl)butan-2-ol;
compound I-6 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-methoxy-pent-3-ynyl]-1,2,4-triazole;
compound I-7 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)butan-2-ol;
compound I-8 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-cyclopropyl-2-methoxy-ethyl]-1,2,4-triazole;
compound I-9 1-[2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-2-methoxy-propyl]-1,2,4-triazole;
compound I-10 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-ol,
compound I-11 1-[2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-2-cyclopropyl-2-methoxy-ethyl]-1,2,4-triazole;
compound I-12 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-methoxy-3,3-dimethyl-butyl]-1,2,4-triazole;
compound I-13 1-[2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-2-methoxy-butyl]1,2,4-triazole;
compound I-14 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)pent-3-yn-2-ol;
compound I-15 1-[2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-2-methoxy-pent-3-ynyl]-1,2,4-triazole;
compound I-16 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)but-3-yn-2-ol;
compound I-17 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-18 2-[2-chloro-4-(4-fluorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-19 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-3-methyl-1-(1,2,4-triazol-1-yl)butan-2-ol;
compound I-20 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-methoxy-propyl]-1,2,4-triazole;
compound I-21 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-methoxy-butyl]-1,2,4-triazole;
compound I-22 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-methoxy-pentyl]-1,2,4-triazole;
compound I-23 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1,1,1-trifluoro-3-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-24 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-3-fluoro-1-(1,2,4-triazol-1-yl)butan-2-ol hydrochloride;
compound I-25 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)pent-4-yn-2-ol;
compound I-26 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-methoxy-3-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-27 2-[2-chloro-4-(4-fluorophenoxy)phenyl]-1-methoxy-3-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-28 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)pentan-2-ol;
compound I-29 and 2-[4-(4-fluorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol;
compound I-30 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)butan-2-ol; and
compound I-31 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)pentan-2-ol;
and
2) as component II a compound selected from the group of sulfoxaflor (II-3); and triflumezopyrim (II-7).
US Pat. No. 10,214,726

COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASE IN A MAMMALIAN SUBJECT

The United States of Amer...

1. A composition comprising a dendritic cell population transduced or transfected with a vector comprising a nucleic acid encoding a human endogenous retrovirus type E (HERV-E) amino acid sequence at least 90% identical to any one of SEQ ID NOs: 1-10 or a HERV-E nucleic acid having a sequence at least 90% identical to any one of SEQ ID NOs: 11, 12, 35-45, or 47.
US Pat. No. 10,214,471

METHOD FOR PRODUCING PROPYLENE GLYCOL FROM PROPENE AND HYDROGEN PEROXIDE

Evonik Degussa GmbH, Ess...

1. A process for preparing 1,2-propanediol from propene and hydrogen peroxide, comprising the steps of:a) reacting propene with hydrogen peroxide in the presence of a catalyst mixture comprising a phase transfer catalyst and a heteropolytungstate, wherein the reaction is carried out in a biphasic liquid mixture comprising an aqueous phase having a pH of at most 6 and an organic phase;
b) separating the biphasic mixture from step a) into an aqueous phase P1 and an organic phase P2 comprising propene oxide;
c) recycling the propene oxide present in the separated organic phase P2 into the reaction of step a); and
d) separating 1,2-propanediol from the aqueous phase P1 separated in step b).
US Pat. No. 10,213,448

ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF

NOVAZOI THERANOSTICS, Ra...

1. A method for treating prostate cancer, comprising administering to a subject in need thereof, an effective amount of a pharmaceutical composition comprising:monoethanolamine or a pharmaceutically acceptable salt thereof; and
a pharmaceutically effective carrier.
US Pat. No. 10,213,704

METHODS AND SYSTEMS FOR REDUCING THE LEVEL OF ONE OR MORE IMPURITIES THAT ARE PRESENT IN A PRETREATED CELLULOSIC MATERIAL AND/OR DISTILLATE

Poet Research, Inc., Sio...

1. A method of reducing the concentration of diacetyl that is present in a distillate comprising:providing a pretreated cellulosic material;
subjecting the pretreated cellulosic material to a fermentation process to form a fermentation product comprising:
an alcohol; and
diacetyl;
distilling the fermentation product to form a distillate comprising the alcohol and the diacetyl; and
contacting the distillate with at least one treatment compound so that the at least one treatment compound reacts with the diacetyl to form a reaction product thereby reducing the concentration of the diacetyl and forming a treated distillate, wherein the at least one treatment compound is chosen from an oxidizing agent and mixtures of the oxidizing agent and an alkali.
US Pat. No. 10,214,728

PANCREATIC ENDOCRINE CELLS, METHOD FOR PRODUCING SAME, AND TRANSDIFFERENTIATION AGENT

Juntendo Educational Foun...

1. A method for producing pancreatic endocrine cells, the method comprisingintroducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells,
wherein the pancreatic endocrine cells are produced without undergoing an iPS cell stage.
US Pat. No. 10,212,937

MICROBICIDAL AQUEOUS SOLUTIONS INCLUDING A MONOCHLORAMINE AND A PERACID, AND METHODS OF USING THE SAME

Buckman Laboratories Inte...

1. An aqueous solution comprising (a) monochloramine in an amount of 1 ppm to 100 ppm, and (b) at least one peracid in an amount of 1 ppm to 100 ppm, wherein the peracid is peracetic acid and wherein components (a) and (b) are present in a synergistically microbicidally effective combined amount to control the growth of at least one microorganism, wherein said synergistically microbicidally effective combined amount is demonstrated by a formula of QA/Qa+QB/Qb, whereinQa=Concentration of said monochloramine in parts per million, acting alone, which produced an end point to completely prevent growth of a bacteria,
Qb=Lowest concentration of said peracid in parts per million, acting alone, which produced an end point to completely prevent growth of said bacteria,
QA=Lowest concentration of said monochloramine in parts per million, in said aqueous solution, which produced an end point to completely prevent growth of said bacteria,
QB=Lowest concentration of said peracid in parts per million, in said aqueous solution, which produced an end point to completely prevent growth of said bacteria,and where the sum of QA/Qa and QB/Qb is less than one, and wherein said bacteria is Pseudomonas aeruginosa or Enterobacter aerogenes.
US Pat. No. 10,213,449

COMPOSITIONS AND METHODS FOR TREATING MEDULLOBLASTOMA

The Board of Trustees of ...

1. A method of treating an individual who has a medulloblastoma tumor, the method comprising:administering a composition to an individual who has a medulloblastoma tumor, at a dose sufficient to reduce the size and/or growth rate of the medulloblastoma tumor, wherein the composition comprises the casein kinase II (CK2) inhibitor 5-(3-Chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945).
US Pat. No. 10,214,473

METHOD FOR PRODUCING ACETIC ACID

DAICEL CORPORATION, Osak...

1. A method for producing acetic acid, comprising:a carbonylation reaction step of reacting methanol with carbon monoxide in the presence of a catalyst system containing a metal catalyst and methyl iodide, as well as acetic acid, methyl acetate, and water in a reaction vessel to produce acetic acid;
an evaporation step of separating a reaction mixture obtained in the carbonylation reaction step into a vapor stream and a residual liquid stream in an evaporator;
a lower boiling point component removal step of separating the vapor stream by a first distillation column into a first overhead stream rich in at least one lower boiling point component selected from methyl iodide and acetaldehyde, and a first acetic acid stream rich in acetic acid, and condensing and separating the first overhead stream to obtain an aqueous phase and an organic phase; and
a first overhead stream recycle step of recycling at least a portion of the aqueous phase and/or the organic phase obtained by condensing the first overhead stream to the reaction vessel,
wherein a crotonaldehyde concentration in the first acetic acid stream is controlled to not more than 2.2 ppm by mass; and
a ratio of CCR/CECR of the crotonaldehyde concentration CCR ppm by mass to the 2-ethyl crotonaldehyde concentration CECR ppm by mass in the first acetic acid stream is not more than 35;
further wherein the ratio of CCR/CECR of the crotonaldehyde concentration CCR ppm by mass to the 2-ethyl crotonaldehyde concentration CECR ppm by mass in the first acetic acid stream is controlled to be not more than 35 by at least one of (a) controlling a hydrogen partial pressure in the reaction vessel to not less than 0.01 MPa and no more than 0.5 MPa or (b) controlling a reflux ratio during the lower boiling point component removal step to not less than 2 and no more than 100.
US Pat. No. 10,214,729

REPROGRAMMING CELLS

The Scripps Research Inst...

1. A composition comprising an induced mammalian pluripotent stem cell (iPSC) and a cell culture medium, wherein:(a) the iPSC comprises an exogenous polynucleotide encoding an Oct4 polypeptide;
(b) the cell culture medium comprises:
(i) a small molecule selected from the group consisting of F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxalylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), and PDK1 activator (3?-phosphoinositide-dependent kinase-1), and
(ii) one or both of a TGF? receptor/ALK5 inhibitor and a MEK inhibitor; and
(c) the iPSC is reprogrammed from a non-pluripotent mammalian cell;
wherein contacting the non-pluripotent mammalian cell with the small molecule enhances reprogramming when compared to without the small molecule.
US Pat. No. 10,213,450

COMBINATION OF BIOLOGICALLY ACTIVE SUBSTANCES FOR TREATMENT OF HYPERGLYCAEMIC DISORDERS

BioActive Food GmbH, Bad...

1. Composition comprising:(a) phlorizin; and
(b) 0.01 to 10 g of one or more inhibitors of lactase phlorizin hydrolase, wherein the inhibitor is selected from the group consisting of quercetin-7-O-glucoside and kaempferol-7-O-glucoside.
US Pat. No. 10,214,730

ADENO-ASSOCIATED-VIRUS REP SEQUENCES, VECTORS AND VIRUSES

The Research Foundation F...

13. A method for producing a recombinant adeno-associated virus (rAAV) particle, comprisinga) providing a vector comprising the recombinant nucleotide sequence of claim 1,
b) providing an adeno-associated virus (AAV) packaging cell, and
c) transfecting the packaging cell with said vector to produce a recombinant adeno-associated virus (rAAV).
US Pat. No. 10,215,754

ANTI-T. CRUZI ANTIBODIES AND METHODS OF USE

Abbott Laboratories, Abb...

1. An immunodiagnostic reagent comprising a monoclonal antibody that specifically binds to a diagnostically relevant region of a T cruzi FP10 polypeptide, or an antigen binding fragment thereof, which monoclonal antibody comprises a variable light chain region (VL) amino acid sequence of SEQ ID NO: 18 and a variable heavy chain region (VH) amino acid sequence of SEQ ID NO: 20.
US Pat. No. 10,212,939

METHYLOBACTERIUM COMPOSITIONS AND PLANTS, PLANT PARTS AND SEEDS COATED THEREWITH

NEWLEAF SYMBIOTICS, INC.,...

2. A plant, plant part, or seed that is coated or partially coated with a composition comprising: (i) a solid substance wherein a mono-culture or co-culture of Methylobacterium is adhered thereto by having been grown on said solid substance, wherein a Methylobacterium in said mono-culture or co-culture is deposited strain NLS0017 (NRRL B-50931); and (ii) an agriculturally acceptable adjuvant, excipient, or combination thereof; and wherein the plant, plant part, or seed is a peanut (Arachis hypogaea) or lettuce (Lactuca sativa) plant, plant part, or seed.
US Pat. No. 10,213,963

METHOD OF ADHERING AND CONVEYOR BELT

The Yokohama Rubber Co., ...

1. A conveyor belt obtained by bonding together conveyor belts to be adhered using an adhesive rubber, whereinthe conveyor belts to be adhered include a rubber composition containing an ethylene-?-olefin copolymer, an organic peroxide (X1), and carbon black (Y1), the organic peroxide (X1) being contained in an amount of from 0.011 to 0.020 molar equivalents relative to the ethylene-?-olefin copolymer in the conveyor belts to be adhered,
the adhesive rubber includes a rubber composition containing an ethylene-?-olefin copolymer, an organic peroxide (X2), and carbon black (Y2), the organic peroxide (X2) being contained in an amount of from 0.017 to 0.022 molar equivalents relative to the ethylene-?-olefin copolymer in the adhesive rubber, and
a content ratio (X2/X1) of the organic peroxide (X2) to the organic peroxide (X1) is from 1.20 to 2.00.
US Pat. No. 10,214,731

ADENO-ASSOCIATED VIRUS MEDIATED DELIVERY OF C1E1 AS A THERAPY FOR ANGIOEDEMA

CORNELL UNIVERSITY, Itha...

1. A method of treating a deficiency in a functional plasma C1 esterase inhibitor in a mammal, or treating or preventing any symptom thereof, comprising administering a recombinant adeno-associated virus (AAV) vector comprising a promoter operably linked to a nucleic acid sequence that encodes human C1 esterase inhibitor (C1EI) to the mammal, whereupon the nucleic acid is expressed to produce a protein.
US Pat. No. 10,215,755

METHOD OF DIAGNOSING AND TREATING EPSTEIN BARR VIRUS-BASED MYALGIC ENCEPHALOMYELITIS CHRONIC FATIGUE SYNDROME PATIENTS

CFS, LLC, Beverly Hills,...

1. A method of identifying a Epstein-Barr virus (EBV) subset of Myalgic Encephalomyelitis-Chronic Fatigue Syndrome patients, the method comprising the step of:incubating EBV Early Antigen, Diffuse and at least one of EBV encoded DNA polymerase or EBV encoded dUTPase with a sample from a Myalgic Encephalomyelitis-Chronic Fatigue Syndrome patient, where the EBV Early Antigen, Diffuse are covalently coupled to microspheres and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase are covalently coupled to microspheres that are different from the EBV Early Antigen, Diffuse coupled microspheres;
detecting binding of serum antibodies from the sample to the EBV Early Antigen, Diffuse and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase; and
identifying the patient with Epstein Barr Abortive Lytic Replication when binding of the serum antibodies to the EBV Early Antigen, Diffuse and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase is detected.
US Pat. No. 10,214,732

LYSIN AGENT AND METHOD OF USE FOR DIAGNOSTIC TESTING

The United States of Amer...

1. A recombinant nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ. ID NO: 2, or fusion thereof.
US Pat. No. 10,215,756

COMPOSITION FOR DIAGNOSING PANCREATIC CANCER AND METHOD FOR DIAGNOSING PANCREATIC CANCER USING THE SAME

SK TELECOM CO., LTD., Se...

1. A method for detecting the expression of protein in a subject suspected of having high-risk intraductal papillary mucinous neoplasm (IPMN), comprising:obtaining a sample from a subject suspected of having pancreatic cancer,
measuring a protein expression level of LRG1 (Leucine-rich alpha-2-glycoprotein 1) from the sample suspected of having high-risk IPMN,
comparing the expression level of LRG1 between the sample from the subject suspected of having high-risk IPMN and a sample from a normal group.
US Pat. No. 10,212,941

METHOD FOR TREATMENT AND CONTROL OF PLANT DISEASE

1. A method of preventing or reducing symptoms or disease associated with Xanthomonas axonopodis pv. citri or Xylella fastidiosa in a plant, comprising contacting said plant with a population of virulent bacteriophage particles that includes Xylella fastidiosa in its host range, wherein the virulent bacteriophage is selected from the group consisting of: the Xfas100 phage type and the Xfas300 phage type;wherein the Xfas100 type phage has the following characteristics:
(a) the bacteriophage is capable of lysing said Xylella fastidiosa and/or Xanthomonas bacteria;
(b) the bacteriophage infects a cell by binding to a Type IV pilus;
(c) the phage belongs to Siphoviridae family and has capsid size ranging from 55-77 nm in diameter;
(d) the genomic size of bacteriophage is about 55500 bp to 56200 bp; and
(e) the bacteriophage prevents or reduces symptoms associated with X. fastidiosa or Xanthomonas axonopodis pv. citri and subspecies thereof, in a plant or plants;
and wherein the Xfas300 type phage has the following characteristics:
(f) the bacteriophage is capable of lysing said Xylella fastidiosa and/or Xanthomonas bacteria;
(g) the bacteriophage infects a cell by binding to a Type IV pilus;
(h) the phage belongs to Podoviridae family and has capsid size ranging from 58-68 nm in diameter;
(i) the genomic size of bacteriophage is about 43300 bp to 44600 bp; and
(j) the bacteriophage prevents or reduces symptoms associated with X. fastidiosa or Xanthomonas axonopodis pv. citri and subspecies thereof, in a plant or plants.
US Pat. No. 10,213,453

CONTROL RELEASE OF FAT SOLUBLE ANTIOXIDANTS FROM AN ORAL FORMULATION AND METHOD

1. A method for increasing the amount of oral absorption of flavonoids into an animal, comprising the following steps:a. selecting an oral formulation comprising a plurality of seed granules each made from calcium carbonate with microscopic fissures formed thereon, wherein disposed inside the microscopic fissures and interstitial spaces are microscopic particles of alkali metal salt, alkali metal hydroxide or other ions, forming a first layer made of microcrystalline cellulose or croscarmellose sodium surrounding the outside surface of said seed granules; forming a second layer comprising a mixture of a flavonoid and polysaccharide or polypeptide binder or polymer gel; forming a third layer surrounding said second layer, said third layer made of microscopic alkaline earth metal salt particles; and forming at least one hardened outer gel layer surrounding said third layer; and,
b. orally consuming said oral formulation.
US Pat. No. 10,214,733

HETEROLOGOUS EXPRESSION OF TERMITE CELLULASES IN YEAST

Lallemand Hungary Liquidi...

1. An isolated polynucleotide comprising a nucleic acid which encodes the mature endoglucanase of SEQ ID NO: 37, wherein said nucleic acid is codon-optimized for expression in a yeast strain wherein at least one nucleotide within a sequence of 4, 5, 6, 7, 8, 9, or 10 consecutive A, T, C or G nucleotides is replaced with a different nucleotide, wherein the nucleotide replacement does not alter the amino acid sequence encoded by the polynucleotide and wherein the nucleotide replacement creates a codon that is the second most frequently used codon to encode an amino acid in the yeast strain.
US Pat. No. 10,212,942

COMBINATIONS COMPRISING A FUNGICIDAL STRAIN AND AN ACTIVE COMPOUND

Bayer CropScience LP, Re...

1. A fungicidal composition for controlling phytopathogenic harmful fungi, comprising1) Bacillus subtilis strain with NRRL Accession No. B-21661 or a mutant thereof having all the identifying characteristics of the strain, and
2) silthiofam,
in a synergistically effective amount.
US Pat. No. 10,213,454

METHODS OF INHIBITING CANCER STEM CELLS WITH HMGA1 INHIBITORS

THE JOHNS HOPKINS UNIVERS...

1. A method of treating an aggressive and/or poorly differentiated metastatic cancer in a subject in need thereof comprising administering a therapeutically effective amount of at least one HMGA1 inhibitor to the subject, wherein the aggressive and/or poorly differentiated metastatic cancer comprises at least one cancer stem cell that overexpresses HMA1 protein.
US Pat. No. 10,214,734

METHOD FOR PRODUCING AN ENZYMATIC COCKTAIL FROM FUNGAL MUST

IFP Energies nouvelles, ...

1. A process for the production of an enzymatic cocktail from a cellulolytic microorganism producing cellulases and/or hemi-cellulases, where the microorganism is a filamentous fungus comprising:a—producing enzymes to obtain a medium containing enzymes and a microorganism must, and separating said must from the liquid containing said enzymes,
b—cooling said must to a temperature between 4 and 20° C., which is a temperature below the temperature of the enzyme production step, for a time of 12 to 90 hours such that:
the beta-glucosidase or ?-xylosidase concentration of liquid originating from cooling is greater than that of the liquid originating from the enzyme production (a), and/or
the solid volume/total volume ratio is less than said ratio for the enzyme production and
c—obtaining an enzymatic cocktail at the end of cooling (b).
US Pat. No. 10,215,758

PLATINUM-LABELED PROBES FOR MASS CYTOMETRY

The Board of Trustees of ...

1. A method of detecting whether an analyte is present on a particle, the method comprising:contacting the particle with an analyte-specific binding reagent conjugated to a platinum-containing moiety under conditions sufficient for analyte-specific binding of the analyte-specific binding reagent to the analyte present on the particle, wherein the platinum-containing moiety, when conjugated to the analyte-specific binding reagent, does not have covalent binding activity; and
determining if the analyte-specific binding reagent conjugated with the platinum containing moiety is associated with the particle by detecting the platinum of the associated analyte-specific binding reagent by elemental mass spectrometry-based detection to detect whether the analyte is present on the particle;
wherein the platinum-containing moiety is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, nedaplatin, lobaplatin, heptaplatin, satraplatin, picoplatin, prolindac, lipoplatin, dichloridobis(isopropylamine)platinum(II) (JM-11), dichloridobis(cyclopentylamine)platinum(II) (NSC 170898), ormaplatin, sebriplatin, enloplatin, zeniplatin, spiroplatin, cycloplatam, miboplatin, iproplatin, [3-Acetyl-5-methyl-2,4(3H,5H)-furandionato-O3,O4][1,2-cyclo-hexanediamine-N,N?]platinum(II) (TRK-710), aroplatin, and [trans-Diamminechloridoplatinum(II)][(?-trans-diamminedihexanediamine-N,N?)platinum(II)] (BBR3464).
US Pat. No. 10,212,943

PLANT GROWTH-PROMOTING MICROORGANISMS AND METHODS OF USE THEREOF

The Regents of the Univer...

1. A method of increasing one or more plant growth characteristics in a plant, comprising: providing to the plant an effective amount of one or more plant growth-promoting microbial isolates selected from the group consisting of Bacillus simplex 30N-5 and Bacillus subtilis 30VD-1.
US Pat. No. 10,213,967

FABRICATING DEVICE OF THREE-DIMENSIONAL SCAFFOLD AND FABRICATING METHOD THEREOF

Academia Sinica, Taipei ...

1. A method of fabricating a 3-D scaffold, comprising steps of:(A) supplying a gel solution and an airflow into a bubble generator to form a plurality of bubbles;
(B) supplying the bubbles into a bubble mixing channel through which the bubbles flow to a bubble collector;
(C) adding a coagulating solution into the bubble mixing channel before the bubbles are collected to result in a gel coagulation effect in the bubble mixing channel;
(D) collecting the bubbles in the bubble collector before the gel coagulation effect is finished; wherein the gel coagulation effect is a reaction that a foam containing the gel solution is coagulated into a solid-state structure; and
(E) communicating with at least a part of the bubbles to form a 3-D scaffold,
wherein the bubble mixing channel is connected to a coagulating solution channel through which the coagulating solution is added, and the bubble mixing channel includes at least a bent portion and a first outlet, the bent portion is disposed between the first outlet and an intersection of the bubble mixing channel and the coagulating solution channel, the bubbles start to contact the coagulating solution at the intersection of the bubble mixing channel and the coagulating solution channel and the gel coagulation effect is thus started; wherein the bubbles are changed in shape because of flowing through the bent portion.
US Pat. No. 10,214,735

HEPARINASES OBTAINED FROM SPHINGOBACTERIUM DAEJEONENSE, PREPARATION THEREFOR AND APPLICATION THEREOF

Shenzhen Hepalink Pharmac...

1. A method for obtaining a purified heparinase with a molecular weight of 74,692 Da and an isoelectric point of 5.64 from a Sphingobacterium daejeonense bacterium, comprising the steps of:(a) inoculating a Sphingobacterium daejeonense strain on a slant medium;
(b) culturing the strain obtained in step (a) in a seed culture medium for 1-2 days, followed by culturing the strain in a secondary liquid seed medium for 1-2 days, and culturing in a fermentation medium for 1-5 days, thereafter collecting cells;
(c) suspending the cells obtained in step (b) and disrupting said cells to obtain a cell supernatant by centrifugation,
(d) conducting an ammonium sulfate precipitation of the cell supernatant of step (c) in an ice bath, collecting a precipitated component with 35%-85% saturation, dissolving the precipitate in a Tris-HCl buffer and dialyzing it to obtain an enzyme solution;
(e) loading the enzyme solution obtained in step (d) onto a Q-Sepharose column and collecting the fractions with heparinase activity from the Q-Sepharose column effluent;
(f) loading the fractions with heparinase activity obtained from step (e) onto a CS column, wherein the CS column is a Cellufine Sulfate affinity column or a heparin-bound affinity column, and collecting fractions with heparinase activity from the CS column effluent;
(g) loading the fractions with heparinase activity obtained from step (f) onto an SP column, wherein the SP column is a strong cation-exchange column, and collecting fractions with heparinase activity from the SP column effluent; and
(h) loading the fractions with heparinase activity obtained from step (g) onto a Sephadex G-100 column, collecting the fractions with heparinase activity from the Sephadex G-100 column effluent, combining said fractions and concentrating the fractions to obtain the purified heparinase having a molecular weight of 74,692 Da and an isoelectric point of 5.64.
US Pat. No. 10,215,759

ELECTROPHYSIOLOGICAL ASSAYS USING OOCYTES THAT EXPRESS HUMAN ENAC AND THE USE OF PHENAMIL TO IMPROVE THE EFFECT OF ENAC ENHANCERS IN ASSAYS USING MEMBRANE POTENTIAL REPORTING DYES

SENOMYX, INC., San Diego...

1. A method of identifying a compound which modulates taste by:(i) contacting a recombinant or isolated mammalian cell or cell population that expresses a functional human Epithelial Sodium Channel (hENaC) comprising a delta subunit which is at least 95% identical to the polypeptide encoded by SEQ ID NO:7 and an alpha and beta subunit which are respectively at least 95% identical to the polypeptides encoded by SEQ ID NO:1 and 2 with at least one compound,
(ii) identifying whether the compound modulates the activity of said functional hENaC; and
(iii) based on whether the compound modulates activity of said hENaC identifying the compound as one potentially modulating taste.
US Pat. No. 10,214,736

MUTANT POLYPEPTIDES AND USES THEREOF

1. A polypeptide comprising an amino acid sequence with at least 90% amino acid sequence homology to SEQ ID NO: 1, wherein said amino acid sequence comprises one to five mutations at the following X positions of SEQ ID NO: 1:R1-95X96R97-98X99R100-122X123R124-186X187R188-203X204R205-211X212R213-272X273X274X275R276-323X324R325-327X328R329-359X360R361-365X366R367-381X382R383-398, wherein:
X96 is mutated to a different amino acid selected from L, I, M, A, G, and V;
X99 is mutated to a different amino acid selected from L, I, M, A, G, and V;
X123 is mutated to a different amino acid selected from L, I, M, A, and G;
X187 is mutated to a different amino acid selected from L, M, A, G, and V;
X204 is mutated to a different amino acid selected from L, I, M, A, and G;
X212 is mutated to a different amino acid selected from F, Y, and W;
X273 is mutated to a different amino acid selected from C, M, S, and T;
X274 is mutated to a different amino acid selected from F, Y, and W;
X275 is mutated to a different amino acid selected from L, I, M, A, and G;
X324 is mutated to a different amino acid selected from L, I, M, G, V, E, D, N, and Q;
X328 is mutated to a different amino acid selected from I, M, A, G, and V;
X360 is mutated to a different amino acid selected from F, Y, and W;
X366 is mutated to a different amino acid selected from L, I, M, A, G, V, C, and T;
X382 is mutated to a different amino acid selected from Y and W; and each R is the same as the corresponding amino acid in SEQ ID NO: 1, with or without an N-terminal signal peptide, and with or without an N-terminal methionine,
wherein the polypeptide is capable of converting 3-buten-2-ol to 1,3-butadiene and/or converting 3-methyl-3-buten-2-ol to isoprene,
and provided that the mutations chosen from one or more of positions X96, X99, X123, and X187 are not the only mutations in SEQ ID NO: 1.
US Pat. No. 10,215,760

DETECTION OF INTRAAMNIOTIC AND/OR INFECTION

Hologic, Inc., Marlborou...

1. A method of diagnosing intra-amniotic infection in a pregnant female mammalian subject comprising:(a) obtaining a test a sample of cervical-vaginal fluid from the subject, wherein the pregnant female mammalian subject has intact membranes, is in pre-term labor, and is from about 22 weeks to about 36 weeks gestation;
(b) detecting the levels of interleukin-6 (IL-6) and alpha-fetoprotein (AFP) in the test cervical-vaginal fluid sample by contacting the sample with detecting agents specific for IL-6 and AFP and detecting binding between the detecting agents and the IL-6 and AFP proteins;
(c) diagnosing said subject with intra-amniotic infection when each of said levels of each of said proteins in said sample is determined to show a statistically significant difference relative to the corresponding levels of each of said proteins in said normal cervical-vaginal fluid; and
(d) performing amniocentesis on the diagnosed subject or treating said subject that is not diagnosed in step (c) for preterm labor.
US Pat. No. 10,212,945

METHOD OF MAKING A MOSQUITO REPELLANT COMPOSITION

1. A method of making a mosquito repellant comprising the steps of:preparing a first solution including the steps of:
cutting fennel plant;
cutting lemon balm leaves;
putting said fennel plant and said lemon balm leaves into water;
boiling said water, fennel plant and lemon balm leaves;
letting said water cool in a container;
adding an antimicrobial preservative to said container;
sealing said container and agitating said container;
storing said container;
straining said water to remove said lemon balm leaves and said fennel plant;
adding to said water:
alcohol free witch hazel;
sodium lactate;
preparing a second solution including:
camelina oil;
mineral oil;
cetyl alcohol;
steric acid;
heating said first solution and said second solution separately from each other;
add said first and second solutions together and mix well to define a mixture;
cool said mixture;
add to said mixture to define a final composition:
antimicrobial preservative;
fragrance;
titanium dioxide;
pouring said final composition into a dispensing bottle.
US Pat. No. 10,213,457

BRAIN AND NEURAL TREATMENTS COMPRISING PEPTIDES AND OTHER COMPOSITIONS

Transdermal Biotechnology...

1. A method, comprising:administering, to the skin of a subject having or at risk of a neurological disorder, a composition comprising an effective amount of molecular nitric oxide and a peptide to treat or prevent the neurological disorder, and a carrier comprising lecithin containing the molecular nitric oxide, wherein the composition is stable at room temperature.
US Pat. No. 10,214,737

THERMOPHILIC AND THERMOACIDOPHILIC METABOLISM GENES AND ENZYMES FROM ALICYCLOBACILLUS ACIDOCALDARIUS AND RELATED ORGANISMS, METHODS

Battell Energy Alliance, ...

1. An expression vector comprising an isolated polynucleotide encoding a polypeptide having at least 90% sequence identity to SEQ ID No. 426 and a nucleotide sequence heterologous to the polynucleotide.
US Pat. No. 10,212,946

MICROBICIDAL COMPOSITION

DOW GLOBAL TECHNOLOGIES L...

1. A microbiocidal composition comprising:(a) N-methyl-1,2-benzisothiazolin-3-one; and
(b) at least one essential oil selected from the group consisting of thyme oil and rosemary oil;wherein when the essential oil is thyme oil, the weight ratio of N-methyl-1,2-benzisothiazolin-3-one to thyme oil is from 1:52 to 1:160,000; andfurther wherein when the essential oil is rosemary oil the weight ratio of N N-methyl-1,2-benzisothiazolin-3-one to rosemary oil is from 1:250 to 1:16,000.
US Pat. No. 10,213,458

DIFFERENTIAL TUMOR CELL CYTOTOXICITY VIA CONTACT WITH COATED CERIUM OXIDE NANOPARTICLES

University of Central Flo...

1. A method of treating cancer comprising:contacting lung cancer cells and normal cells with cerium oxide nanoparticles comprising a polyacrylic acid coating with a negative surface charge, under conditions such that the cerium oxide nanoparticles are internalized in the lung cancer cells but not the normal cells, thereby providing a cytotoxic result for the lung cancer cells.
US Pat. No. 10,214,738

PRODUCTION OF HIGH PURITY CHONDROITINASE ABC

Advantek Serum Laboratori...

1. A matrix of a material comprising one or more microorganism(s) to produce chondroitinase ABC, the microorganisms selected from genetically-modified Escherichia coli, genetically-modified Bacillus subtilis, Proteus vulgaris, Pichia pastoris, and/or Saccharomyces cerevisiae; and wherein said one or more microorganism(s) expresses or expressed the chondroitinase ABC comprising the amino acid sequence set forth in SEQ ID NO: 3.
US Pat. No. 10,215,762

METHOD TO OPTIMIZE THE TREATMENT OF PATIENTS WITH BIOLOGICAL DRUGS

Progenika Biopharma, S.A....

1. A method of treating a patient, comprising:providing a patient sample, wherein (a) the patient sample is blood, plasma, or serum obtained from a patient suffering from rheumatoid arthritis and receiving a treatment comprising the administration to the patient of a biological drug selected from infliximab and adalimumab; (b) the patient has received at least one dose of the biological drug; and (c) the sample was obtained at a time t1 between two successive administrations of the biological drug;
determining the concentration of the biological drug in the patient sample; and
determining the concentration of antibodies against the biological drug in the patient sample;
comparing the concentration of the biological drug in the patient sample with a Reference Value 1 (RV1), wherein RV1 is a therapeutic efficiency cut-off value of the concentration of the circulating biological drug;
determining that the concentration of the biological drug in the patient sample is greater than or equal to RV1;
comparing the concentration of antibodies against the biological drug in the patient sample with a Reference Value 2 (RV2), wherein RV2 is a cut-off value of the concentration of the antibodies against the biological drug as determined in a group of treatment-naïve individuals;
determining that the concentration of antibodies against the biological drug in the patient sample is less than or equal to RV2;
classifying the patient as a responder to the biological drug; and
re-administering the biological drug to the patient because the patient is classified as a responder,
wherein:
the re-administering of the biological drug is the second of the two successive administrations of the biological drug;
when the biological drug is infliximab, then RV1 is 1.5 ?g/ml and RV2 is 150 ng/ml; and
when the biological drug is adalimumab, then RV1 is 0.8 ?g/ml and RV2 is 32 ng/ml.
US Pat. No. 10,213,459

COMPOSITIONS OF FUNCTIONAL MITOCHONDRIA AND USES THEREOF

MINOVIA THERAPEUTICS LTD....

1. A pharmaceutical composition comprising:a plurality of partially purified functional human mitochondria that have undergone a freeze-thaw cycle, the plurality of partially purified functional human mitochondria having an oxygen consumption rate comparable to or higher than that of control mitochondria that have not undergone a freeze-thaw cycle, the partially purified functional human mitochondria having an intact outer membrane; and
sucrose in an amount sufficient to preserve mitochondrial function,
wherein the total amount of mitochondrial proteins is between 20%-80% of the total amount of cellular proteins within said composition, and
wherein the composition is devoid of exogenous protease inhibitors.
US Pat. No. 10,214,483

TITANIUM-SILICALITE MOLECULAR SIEVE, METHOD FOR PREPARING THE SAME AND METHOD FOR PREPARING CYCLOHEXANONE OXIME USING THE MOLECULAR SIEVE

China Petrochemical Devel...

1. A method for preparing cyclohexanone oxime, comprising the step of:performing a reaction of cyclohexanone, ammonia and hydrogen peroxide in the presence of a titanium-silicalite molecular sieve as a catalyst and a solvent, wherein the titanium-silicalite molecular sieve comprises a silicon oxide, a titanium oxide, and a metal oxide, wherein a metal of the metal oxide is at least one selected from IIA, IIIA, and IVA elements, with a molar ratio of titanium to silicon in a range of from 0.005 to 0.1 and a molar ratio of the metal to the silicon in a range of from 0.00001 to 0.05.
US Pat. No. 10,214,739

RNA BINDING SOLUTION

1. A buffer, comprising:a phenol-free RNA-binding buffer that allows RNA to bind selectively to an RNA-binding solid phase comprising:
(a) at least one chaotropic agent; and
(b) an organic solvent selected from the group consisting of ethylene carbonate or, ethylene glycol diacetate or a combination thereof.
US Pat. No. 10,215,763

METHODS FOR ESTIMATING PRION CONCENTRATION IN FLUIDS AND TISSUE BY QUANTITATIVE PMCA

BOARD OF REGENTS OF THE U...

1. A method for preparing a calibration curve useful for quantitatively estimating a concentration of PrPSc in a sample, the method comprising:preparing a plurality of stock solutions, each stock solution in the plurality of stock solutions having a known different concentration of PrPSc;
separately mixing each of the plurality of stock solutions with PrPC to form a plurality of separate stock reaction mixes;
forming a plurality of separate amplified portions of PrPSc by:
performing a plurality of protein misfolding cyclic amplification (PMCA) cycles on each of the plurality of separate stock reaction mixes to form a plurality of separate amplified stock reaction mixes comprising the plurality of separate amplified portions of PrPSc, each cycle in the plurality of PMCA cycles comprising:
incubating each stock reaction mix; and
disaggregating aggregates formed in each stock reaction mix;
subjecting each of the plurality of separate amplified stock reaction mixes to an assay for a number of cycles of the plurality of PMCA cycles until a PrPSc signal is detected; and
determining the calibration curve according to the known different concentration of the PrPSc in each stock solution with the number of PMCA cycles corresponding to detection of the PrPSc signal, at least a portion of the known different concentrations of PrPSc among the plurality of stock solutions being below a concentration detectable by the assay such that the calibration curve provides for quantitative estimation of PrPSc concentration in the sample below the concentration detectable by the assay.
US Pat. No. 10,213,460

MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES

Indiana University Resear...

1. A method of enhancing the mobilization of hematopoietic stem and/or progenitor cells from the bone marrow to the peripheral blood in a cell donor, comprising the steps of:contacting the hematopoietic stem and/or progenitor cells in the donor with an effective amount of a compound, wherein said compound is an inhibitor of COX-2, thereby enhancing mobilization of hematopoietic stem and/or progenitor cells compared to the mobilization of hematopoietic stem and/or progenitor cells that have not been contacted with the compound, wherein the hematopoietic stem and/or progenitor cells are CD34+ and/or colony forming unit-granulocyte/macrophage (CFU-GM) cells.
US Pat. No. 10,213,716

ELECTRET

TOYOBO CO., LTD., Osaka-...

1. An electret, comprising:a carrier, and
polytetrafluoroethylene,
wherein the polytetrafluoroethylene has a melting point of 35° C. or higher and 320° C. or lower and is deposited on the carrier, and
wherein an electrostatic charge is imparted to at least one of the carrier and the polytetrafluoroethylene.
US Pat. No. 10,215,764

ASSAY REAGENTS FOR A NEUROGRANIN DIAGNOSTIC KIT

THE JOHNS HOPKINS UNIVERS...

1. A method of diagnosing brain injury in a patient, the method comprising:(a) detecting whether neurogranin biomarker is present in a biological sample obtained from the patient by contacting the sample with isolated monoclonal antibody designated 30.5.2 (ATCC Deposit Designation PTA-123496), or an antigen binding fragment thereof, and detecting binding between the neurogranin biomarker and monoclonal antibody 30.5.2 (ATCC Deposit Designation PTA-123496), or an antigen binding fragment thereof; and
(b) diagnosing the patient with brain injury when the presence of neurogranin biomarker is detected in the sample.
US Pat. No. 10,214,741

METHODS AND COMPOSITIONS FOR INHIBITING RETINOPATHY OF PREMATURITY

UNIVERSITY OF UTAH RESEAR...

1. A method of treating retinopathy of prematurity (ROP) comprising administering to a subject a composition comprising a vector, wherein the vector comprises a polymerase II (pol II) promoter and a first shRNA, wherein the first shRNA is embedded in microRNA, and wherein the first shRNA has a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in STAT3, VEGFR2, or EPOR mRNA, and wherein the composition is administered via subretinal injection, wherein the first shRNA consists of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.
US Pat. No. 10,215,765

DETECTION OF VITAMINS A AND E BY TANDEM MASS SPECTROMETRY

Quest Diagnostics Investm...

1. A method for determining the amount of vitamin A in a sample by tandem mass spectrometry, said method comprising:a. subjecting vitamin A from a sample to ionization under conditions suitable to produce one or more ions detectable by mass spectrometry; and
b. determining the amount of one or more of said ions by tandem mass spectrometry, wherein tandem mass spectrometry comprises fragmenting a vitamin A precursor ion having a mass to charge ratio of about 269.30±0.80 into one or more fragment ions comprising a fragment ion having a mass to charge ratio of about 105.00±0.80;
wherein the amount of the one or more fragment ions determined in step (b) is related to the amount of vitamin A in the sample.
US Pat. No. 10,213,462

GALECTIN-3 PLASMAPHERESIS THERAPY

ELIAZ THERAPEUTICS, INC.,...

1. A method of treating a disease characterized by a tumor in a mammal, comprising:Selectively removing an amount of galectin-3 (gal-3) from blood from said mammal and selectively removing an amount of soluble tumor necrosis factor (TNF) receptors from said blood from said mammal; and
Reintroducing said blood to said mammal, such that said mammal's blood exhibits a level of gal-3 and soluble TNF receptors following said treatment lower than said blood prior to said treatment.
US Pat. No. 10,214,486

PROCESS AND REACTOR SYSTEM FOR OXIDIZING CYCLOALKYLBENZENE

ExxonMobil Chemical Paten...

1. A process for oxidizing cycloalkylbenzene in an oxidation reactor comprising a reactor body and a liquid distributor comprising liquid ingress ports, the liquid distributor housed inside the reactor body, the process comprising:(I) supplying a cycloalkylbenzene-containing liquid through the liquid distributor into the reactor body; and
(II) contacting the cycloalkylbenzene-containing liquid with an O2-containing gas in the reactor body;
wherein the liquid distributor is arranged such that during normal operation of the oxidation reactor: (a) the liquid reaction medium inside the reactor body above the liquid distributor is agitated at least partly by the flowing liquid supplied from the liquid distributor; and (b) the liquid reaction medium above the liquid distributor has a concentration variation of the cycloalkylbenzene not higher than 20%.
US Pat. No. 10,213,463

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

SMART Surgical, Inc., Bo...

1. A method for performing a medical therapy in a human subject comprising:providing a composition comprising:
a low pH fluid base, wherein the low pH fluid base comprises dextrose;
mononuclear cells obtained from human umbilical cord blood; and
albumin, wherein the concentration of albumin is between about 10 mg/ml and about 150 mg/ml; and
implanting within, near, or adjacent to tissue of the subject an effective amount of the composition.
US Pat. No. 10,214,743

COLORECTAL CANCER DRUG, AND METHOD FOR PREDICTING PROGNOSIS OF COLORECTAL CANCER PATIENT

Hirofumi Yamamoto, Suita...

1. A method of treating a colorectal cancer, comprising a step of administering a therapeutically effective amount of either one or both of miR4689 and miR4685-3p to a patient with the colorectal cancer.
US Pat. No. 10,212,952

COMPOSITION AND METHOD TO SUPPRESS WHEY FLAVOR

Kraft Foods Group Brands ...

1. A whey containing cream cheese comprising:cream cheese curd;
whey protein concentrate;
fat, but no more than about 10% fat;
about 0.01 ppm to about 1 ppm thaumatin to mask flavor notes imparted to the cream cheese from the whey protein concentrate; and
a ratio of whey from the whey protein concentrate to the thaumatin from about 1,200,000:1 to about 4000:1,
wherein the thaumatin is the only sweetener added.
US Pat. No. 10,213,464

METHOD FOR ENHANCING ENGRAFTMENT OF HAEMATOPOETIC STEM CELLS

SCIPHARM SARL, Mertert (...

1. A method for enhancing engraftment of haematopoietic stem cells (HSCs) by an ex vivo pretreatment of the HSCs which comprises the following steps:a. obtaining a sample containing haematopoietic stem cells,
b. admixing with said sample at least one prostacyclin analogue, wherein the prostacyclin analogue is selected from the group consisting of treprostinil, iloprost, and beraprost or pharmaceutically acceptable salts thereof, and forskolin to obtain a mixture,
c. incubating said mixture for a period of time sufficient to stimulate G alpha-signalling in said cells, and optionally
d. isolating said stimulated cells.
US Pat. No. 10,214,744

NUCLEIC ACID MOLECULES INDUCING RNA INTERFERENCE, AND USES THEREOF

Sungkyunkwan University F...

1. An RNAi-inducing nucleic acid molecule comprising:a first strand of 24-119 nt length comprising a region 100% complementary to a target nucleic acid, wherein the region 100% complementary to the target nucleic acid comprises the 19 most 5? nucleic acids of the first strand; and
a second strand of 16 nt length that binds complementarily to the region of the first strand 100% complementary to the target nucleic acid,
wherein the second strand binds to the first strand such that the first strand has a double-stranded region to which the second strand binds and a single-stranded region of 10-15 nucleotides in length to which the second strand does not bind, and wherein the 5? end of the first strand and the 3? end of the second strand form a blunt end.
US Pat. No. 10,214,745

TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF

The Scripps Research Inst...

1. A method of upregulating the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 10 to 30 nucleotides in length wherein said at least one antisense oligonucleotide is at least 90% complementary to and specifically hybridizes to a 10 to 30 nucleotide region of a natural antisense polynucleotide of the BDNF polynucleotide in a 225-nucleotide overlapping region of the natural antisense polynucleotide, wherein said natural antisense polynucleotide consists essentially of a sequence selected from the group consisting of: nucleotides 1 to 1279 of SEQ ID NO: 3, comprising the 225-nucleotide overlapping region at nucleotides 303 to 527, 1 to 1478 of SEQ ID NO: 4, comprising the 225-nucleotide overlapping region at nucleotides 372 to 596; 1 to 1437 of SEQ ID NO: 5, comprising the 225-nucleotide overlapping region at nucleotides 303 to 527; 1 to 2322 of SEQ ID NO: 6, comprising the 225-nucleotide overlapping region at nucleotides 372 to 596; 1 to 2036 of SEQ ID NO: 7, comprising the 225-nucleotide overlapping region at nucleotides 303 to 527; and 1 to 2364 of SEQ ID NO: 8, comprising the 225-nucleotide overlapping region at nucleotides 402 to 626; thereby upregulating the expression of the BDNF polynucleotide.
US Pat. No. 10,212,954

PET FOOD COMPOSITIONS INCLUDING PROBIOTICS AND METHODS OF MANUFACTURE AND USE THEREOF

Colgate-Palmolive Company...

1. A pet food composition, consisting of a plurality of probiotic-coated pellets that meet nutritional requirements of a pet,wherein the plurality of the probiotic-coated pellets consist of ingredients to meet the nutritional requirements for the pet, a starch source, and a topical coating,
wherein the topical coating consists of a live probiotic microorganism and soybean oil,
wherein the starch source has a degree of gelatinization less than about 7.5 Joules/g of starch following extrusion,
wherein the probiotic coated pellets are semi-moist pellets, and
wherein the live probiotic microorganism is one or more of the genera: Bifidobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, or Lactobaccillus.
US Pat. No. 10,213,466

METHODS OF USING LACTIC ACID BACTERIA AS PROBIOTIC STRAINS

Probioswiss Ag, Beckenri...

1. A method of establishing, maintaining or restoring a healthy urogenital flora and environment in a female or a healthy gastrointestinal flora or environment in a human comprising administering to said female or said human a probiotic composition comprising an effective amount of at least one probiotic strain of the genus L. crispatus, L. gasseri, L. helveticus and L. jensenii selected from the group consisting of L. crispatus KS 116.1 (CNCM I-3483), L. crispatus KS 119.4 (CNCM I-3484), L. crispatus 127.1 (CNCM I-3486), L. gasseri KS 114.1 (CNCM I-3482), L. gasseri KS 120.1 (CNCM I-3218), L. gasseri KS 123.1 (CNCM I-3485), L. gasseri KS 124.3 (CNCM I-3220), L. helveticus KS 300 (CNCM I-3360), L. jensenii KS 119.1 (CNCM I-3217) and L. jensenii KS 121.1 (CNCM I-3219).
US Pat. No. 10,214,746

SOYBEAN TRANSFORMATION METHOD

Dow AgroSciences LLC, In...

1. A method of selecting soybean germline transformants, the method comprising:a. transforming a population of cells of a soybean plant with a transgene, wherein the population of transformed cells comprises transformed germline cells and transformed non-germline cells;
b. regenerating shoots from the population of transformed cells;
c. isolating the shoots produced by the population of transformed cells;
d. subjecting the isolated regenerated shoots to a selective rooting medium comprising glufosinate, wherein (i) the subjected isolated regenerated shoots produced by the transformed germline cells create viable roots, and (ii) the subjected isolated regenerated shoots produced by the transformed non-germline cells do not create viable roots; and
e. selecting soybean germline transformants based on the ability of the selected transformants to create viable roots in the glufosinate-containing rooting medium.
US Pat. No. 10,212,955

FORMULA FOR A FOOD DECORATING PAINT FOR APPLICATION ON THE SURFACE OF FOOD OBJECTS

1. A ready to directly apply to food surfaces decorative mixture comprising:A) a base application mixture comprising:
1) a white colorant,
2) water,
3) sugar,
4) sodium chloride,
5) modified food starch, and
6) flavoring,
B) a colorant,
C) an emulsifier comprising a vegetable gum,
D) a pH additive comprising citric acid, and
E) wherein said base application mixture, said colorant, said emulsifier, and said pH additive are premixed together and then added to said water and heated to a boiling temperature,
F) wherein said white colorant in said decorative mixture comprises:
1) calcium carbonate in an amount from about 32% to about 53% by weight of the decorative mixture, and
2) titanium dioxide in an amount from about 0.4% to about 20% by weight of the decorative mixture, wherein said decorative mixture is ready to directly apply to said food surfaces.
US Pat. No. 10,213,467

METHOD FOR IMPROVING MITOCHONDRIA AND METHOD FOR PROMOTING CELL DIVISION OF STEM CELL

TAIWAN MITOCHONDRION APPL...

1. A method for improving the ability of mitochondria to perform oxidative phosphorylation (OXPHOS) and adenosine triphosphate (ATP) synthesis in the cells of a subject in need thereof, the method comprising:administering to said subject an effective amount of a composition containing an Emblica officinalis extract,
wherein the concentration of the Emblica officinalis extract in the composition is from 20 ?g/ml to 50 ?g/ml; and
wherein the Emblica officinalis extract comprises 35% to 55% by weight of a mixture of Emblicanin-A and Emblicanin-B, 4% to 15% by weight of Ponigluconin, 10% to 20% by weight of Pedunculagin, 5% to 15% by weight of Rutin and 10% to 30% by weight of Gallo-ellagitannoids.
US Pat. No. 10,214,747

METHOD OF PURIFYING MONOCLONAL ANTIBODIES

KENTUCKY BIOPROCESSING, I...

1. A method of purifying monoclonal antibodies, following their production in a source organism, said method including the steps of:a) harvesting monoclonal antibody sources from the source organism;
b) extracting said antibodies from said source organism and clarifying the antibodies;
c) processing said extracted and clarified antibodies through a series of chromatography separation procedures, i) wherein a first procedure includes an affinity column from which the target antibody is eluted with an arginine-containing acidic buffer to form an eluent containing full-length monomeric antibody structures, ii) wherein a second procedure includes an ion-exchange column for separating and collecting the full-length antibody monomeric structures from the eluent of step “c(i)”, and iii) wherein a third procedure includes a multimodal column from which the target antibody is eluted over a gradient established between at least one salt, during which the monomeric antibody structures are collected;
d) subjecting the collected antibody structures from step “c(iii)” to a buffer extraction step;
e) filtering said collected antibody structure fraction through a multiple filter press operation; and
f) collecting the resultant filtered monoclonal antibody formulations and storing the same for utilization as a bulk drug substance;
wherein extracting antibodies from said source organism in step “b” is performed with an extraction formulation comprising an alkaline buffer, an antioxidant and a chelating agent, and wherein before performing step “c(ii)” the antibody eluent of step “c(i)” is neutralized to a pH that is at least 0.2 units below the isoelectric point for the antibody.
US Pat. No. 10,212,956

COMPOSITIONS AND METHODS OF TREATING EDIBLE MATTER AND SUBSTRATES THEREFOR

PIMI AGRO CLEANTECH LTD.,...

1. A method for protecting edible matter from decay, comprising contacting edible matter or a substrate therefor with a composition comprising:(1) water,
(2) at least one of: (a) phosphonic acid (HP(O)(OH)2) or a salt thereof and (b) phosphoric acid,
(3) a carboxylic acid,
(4) a surfactant,
(5) at least one of: (i) a performic acid source and (ii) an oxidizer which can oxidize said performic acid source to performic acid, and
(6) performic acidsaid contacting being(i) for a time and
(ii) in an amount of composition and/or at a concentration of composition sufficient to protect said edible matter from said decay, wherein the composition is such that at a concentration of 20 ppm performic acid and a contact time of up to one minute at room temperature, the composition achieves a 10000-fold (4 log) reduction in the cfu of a pathogen grown on a designed growth medium, wherein the pathogen is at least one of the pathogens in the group consisting of Escherichia coli (ATCC 8739), Staphylococcus aureus (ATCC 6538), Pseudomonas aeruginosa (ATCC 9027), Enterococcus hirae (ATCC 10541), Candida albicans (ATCC 10231), Aspergillus niger (ATCC 16404), Listeria monocytogenes (ATCC 19115) and Penecillium w.t. (wild type).
US Pat. No. 10,213,468

TREATMENT OF VIRUS-BASED DISEASES OF THE SKIN

IXCELA, INC., Bedford, M...

1. A method for treating herpes simplex virus type-1 in a human in need thereof consisting essentially of topically administering to the skin of the human in need thereof a therapeutically effective amount of an aqueous or aqueous/alcohol extract of Mongolian dandelion and an oil selected from the group consisting of flax oil, almond oil, coconut oil, jojoba oil, lemon oil, olive oil, sesame seed oil, and sunflower oil.
US Pat. No. 10,213,469

HERBAL PREPARATION FOR ACCELERATING WOUNDS AND SKIN INFLAMMATIONS HEALING AND ITS APPLICATION

Wyzsza Szkola Medyczna w ...

1. A herbal preparation in the form of an ointment comprising a plant extract emulsified or suspended in an organic based medium characterized in that it contains, as an active substance, an alcoholic extract from Melittis melissophyllum L., and other active substances namely flavonoids in the amount of from 3.6% to 13.4% by weight, polyphenols in the amount of from 11.25% to 45% by weight, tannins in the amount of from 5% to 8% by weight, amine compounds in the amount of from 0.475% to 1.9% by weight, bitter substances in the amount of from 11.55% to 46.2% by weight, and mineral salts in the amount of from 6% to 10% by weight, used for an accelerated treatment of wounds and skin inflammations accompanied by an increase in the amount and phagocytic activity of neutrophils from the surface of the healing wounds and skin, without causing side effects.
US Pat. No. 10,217,566

CERAMIC MATERIAL AND CAPACITOR COMPRISING THE CERAMIC MATERIAL

EPCOS AG, (DE)

1. A capacitor comprising:at least one ceramic layer composed of a ceramic material for capacitors using multilayer technology of formula (I):
Pb(1?1.5a+e)Aa(Zr1?xTix)(1?c?e)CeSicO3+y·PbO  (I)whereinA is selected from the group consisting of La, Nd, Y, Eu, Gd, Tb, Dy, Ho, Er and Yb;
C is selected from the group consisting of Ni and Cu; and
0 0.05?x?0.3
0?c<0.12
0.001 0?y<1, and
a conductive electrode formed on the at least one ceramic layer, wherein the current-carrying capacity at 100° C. is at least 1A/?F.
US Pat. No. 10,213,470

METHOD FOR TREATING SPINOCEREBELLAR ATAXIAS

NATIONAL TAIWAN NORMAL UN...

1. A method for treating spinocerebellar ataxias, comprising: administering a pharmaceutical composition comprising therapeutically effective amounts of Paeonia lactiflora and Glycyrrhiza uralensis to a subject in need,wherein a preparation of the pharmaceutical composition comprises:
providing 50 wt % of the Paeonia lactiflora and 50 wt % of the Glycyrrhiza uralensis to form a mixture;
concentrating the mixture to form an extract.
US Pat. No. 10,214,750

SYSTEMS AND METHODS FOR CELL TRANSDUCTION

The Charles Stark Draper ...

1. An apparatus comprising:a first substrate defining at least one first flow chamber coupled to a first fluid manifold;
a second substrate defining a cell entrainment layer, the cell entrainment layer including:
at least one second flow chamber;
a plurality of cell entrainment cavities, wherein each of the cell entrainment cavities opens at one end into one of the at least one second flow chambers, extends through the second substrate, and is sized to hold at least one cell;
at least one inlet to the at least one second flow chamber substantially within the plane of the second substrate; and
at least one outlet from the at least one second flow chamber substantially within the plane of the second substrate;
a first membrane positioned between the first substrate and the second substrate, the first membrane includes a plurality of pores that are small enough to prevent the passage of cells and large enough to allow the passage of a virus;
a third substrate defining at least one third flow chamber coupled to a second fluid manifold; and
a second membrane positioned between the second substrate and the third substrate, the membrane includes a second plurality of pores that are small enough to prevent the passage of viral particles but large enough to allow the passage of cell media.
US Pat. No. 10,212,959

PRODUCTION OF FOOD AND BEVERAGE PRODUCTS FROM BARLEY GRAIN

COMMONWEALTH SCIENTIFIC A...

1. Barley grain comprising:a) a starch content of which at least 40% (w/w) is amylose,
b) a null mutation of a gene encoding starch synthase IIa (SSIIa), wherein the barley grain is homozygous for the null mutation,
c) a level or activity of a starch synthase IIIa (SSIIIa) protein which is less than 25% of the level or activity relative to that of the SSIIIa protein in barley grain of variety Himalaya, and
d) a starch content of 41-65% (w/w).
US Pat. No. 10,214,751

METHOD AND DEVICE FOR TREATING BIOMASS AND ORGANIC WASTE

CAMBI TECHNOLOGY AS, Ask...

1. A method for treating a biomass material comprising at least the steps of:pre-treatment of said biomass material comprising the steps of:
1) thermal hydrolysis at a temperature above 140° C., followed by
2) wet explosion resulting in an intermediate product having a dry matter concentration above 25%, a pH below 6 and a temperature above 90° C.;
subsequent fermentation of said intermediate product in a digestion tank,
wherein said intermediate product is introduced into said digestion tank by mixing said intermediate product into part of a content of said digestion tank being transported in a recirculation loop emerging from said digestion tank,
wherein said mixing is performed before the mixture of said intermediate product and said part of the content of said digestion tank enters said digestion tank,
wherein said part of the content of said digestion tank has a pH in a range of 7-8.5, and
wherein the pH after said mixing and before the mixture enters said digestion tank is above pH 6.
US Pat. No. 10,212,960

MECHANICAL PROCESSES FOR SEPARATING TALLOW AND LEAN BEEF FROM A SINGLE BONELESS BEEF SUPPLY

1. A method for separating fat from beef pieces containing fat, comprising:with an apparatus, reducing the size of beef pieces containing fat into a mixture of particles that are one of two colors, wherein fat particles that comprise predominantly fat are a first of the two colors, and lean particles that comprise predominantly lean are a second of the two colors, and wherein the fat particles and the lean particles are contacted with a fluid comprising aqueous carbonic acid, liquid carbon dioxide and water, an aqueous alkaline solution, or an aqueous acid;
with an apparatus, separating the fat particles from the lean particles based on the fat particles being the first color and the lean particles being the second color.
US Pat. No. 10,213,472

FERMENTED PENNISETUM EXTRACT

Sagittarius Life Science ...

1. A method for treating lung cancer and/or invasion and metastasis of lung cancer in a subject in need thereof, comprising administering to the subject an effective amount of a fermented Pennisetum alopecuroides extract, wherein the fermented Pennisetum alopecuroides extract comprises a compound ZG5236 giving rise to a chromatograph having at least a peak at retention times of 17.18 to 17.98 minutes assayed by HPLC.
US Pat. No. 10,214,752

BIOSYNTHESIS OF 1,3-BUTANEDIOL

INVISTA NORTH AMERICA S.A...

1. A method of producing 3-oxo-5-hydroxypentanoyl-CoA in a recombinant host, said method comprising:enzymatically producing 3-hydroxypropionyl-CoA from malonyl-CoA using a polypeptide having CoA transferase activity, wherein said polypeptide having a CoA transferase has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 5, 6, 7, 12 or 13; and
enzymatically converting 3-hydroxypropionyl-CoA to 3-oxo-5-hydroxypentanoyl-CoA using a polypeptide having ß-ketothiolase activity classified under EC. 2.3.1.-, wherein said polypeptide having ß-ketothiolase activity has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NOs: 1 or 2 and is capable of converting 3-hydroxypropionyl-CoA to 3-oxo-5-hydroxypentanoyl-CoA,
wherein at least one of said polypeptides is encoded by an exogenous nucleic acid sequence.